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Zusammenfassung 
Krebserkrankungen rangieren nach wie vor unter den drei häufigsten Todesursachen der Welt. 
Gleichzeitig steigt die Lebenserwartung in den Industrieländern stetig, sodass die Notwendigkeit 
besteht neue Therapieansätze zu entwickeln, die einerseits die Überlebensrate verbessern und 
andererseits die oft erheblichen Nebenwirkungen der Krebstherapie reduzieren. Elementarer 
Bestandteil dieses Bestrebens ist es die Krebstherapie weiter zu individualisieren. Mesenchymale 
Stammzellen (MSC) aus dem Knochenmark besitzen eine starke Neigung dazu malignes Gewebe 
aufzuspüren und das Tumorstroma zu infiltrieren. Daher bieten sie eine Möglichkeit den Tumor 
gezielt zu attackieren. Durch genetische Manipulation der MSC kann es gelingen jede Tumorart auf 
eine individuelle Art und Weise anzugreifen.  
Das Ziel der vorliegenden Arbeit war es, die MSC mit einem therapeutischen Gen auszustatten, 
welches sich gezielt gegen das Tumorstroma richtet. Dazu wurden drei verschiedene Strategien 
untersucht: das inflammatorische Milieu des Stromas speziell anhand der Über-Expression von 
chemokine-ligand 5 (CCL5/Rantes) anzugreifen, die hypoxischen Areale eines schnell wachsenden 
Tumors zu nutzen oder letztlich, um einen Weg zu finden das therapeutische Gen in den MSC von 
extern zu aktivieren, einen Hyperthermie-sensiblen Promoter einzusetzen. Vorangegangene 
Arbeiten dieser Arbeitsgruppe bewiesen im Mausmodell den Nutzen einer Therapie mit MSC, 
welche CCL5/Rantes-gesteuert eine Thymidinkinase des Herpes-Simplex-Virus exprimierten. 
Anfängliche Experimente dieser Arbeit zielten darauf ab diese CCL5/Rantes-Überexpression der das 
Tumorstroma infiltrierenden MSC zu verstehen. Dabei stellte sich heraus, dass eine Kombination aus 
mehreren inflammatorischen Zytokinen, in der Hauptsache Tumor-Nekrose-Faktor-α, Interleukin-1β 
und Interferon-γ, dafür verantwortlich ist, nicht jedoch die in einem wachsenden Tumor 
vorherrschende Hypoxie. Letztere sorgt lediglich für eine Überexpression des Transkriptionsfaktors 
HIF-1α (hypoxia-inducible factor 1α) durch MSC. Daher wurde im Folgenden ein Konstrukt 
entwickelt, welches die Expression eines Reportergens, in diesem Fall die Firefly Luciferase (pGL3-
hypxia-luc) beziehungsweise das mCherry Fluoreszenzprotein (pGL3-HIF-Cherry), unter die Kontrolle 
eines HIF-1α-sensiblen Promoters stellt. Um die Machbarkeit eines solchen Ansatzes in der Therapie 
mit MSC nachzuweisen, wurden als in vitro-Modell Tumorsphäroide aus humanen 
Leberzellkarzinomzellen herangezüchtet. In Co-Kultur mit MSC, welche zuvor mit dem oben 
genannten Konstrukt pGL3-HIF-Cherry stabil transfiziert worden waren, zeigte sich, dass letztere die 
Fähigkeit besitzen in die Tumorsphäroide einzuwandern und im hypoxischen Zentrum das 
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gewünschte Gen zu exprimieren. Um der Möglichkeit einer externen Aktivierung des 
Expressionsgens nachzugehen, wurde ein weiteres Konstrukt entworfen, welches anstelle eines HIF-
1α-sensitiven Promotors den endogenen HSP70b-Promotor aus der Familie der Heat-Shock-Proteine 
trägt. Durch Exposition der transfizierten MSC gegenüber einem Temperaturanstieg auf 42° Celsius 
ließ sich in vitro eine deutliche Überexpression des Reportergens erzielen.  
Diese Arbeit erbringt den Nachweis, dass die genetische Manipulation mesenchymaler Stammzellen 
aus dem Knochenmark zum Zwecke eines zielgerichteten Angriffs auf das Tumorstroma eine gute 
Möglichkeit darstellt, die Tumortherapie weiter zu individualisieren.  
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Summary 
Malignant diseases range among the top three causes of death worldwide. With increasing overall 
life expectancies, the need for individually tailored, tumor-specific therapies with less detrimental 
side effects than conventional radio- or chemotherapy is rising. Mesenchymal stem cells (MSC) 
possess an innate tropism for the tumor microenvironment, which resembles a chronic wound. This 
has rendered them a flexible, reliable tool for the delivery of therapeutic agents to sites of malignant 
growth.  
The goal of the present study was to study different approaches for the engineering of MSC to 
specifically induce the expression of transgenes within tumor microenvironments. To this end, three 
gene promoter systems, that become activated through different mechanisms, were investigated: 
inflammatory induction of the gene promoter for chemokine ligand 5 (CCL5/Rantes), the 
transcriptional response to tumor hypoxia using a synthetic promoter, and finally, the induced 
expression of transgenes via heat-shock responsive gene promoters following the external 
application of hyperthermia. Previous work by our group has shown the general efficacy of 
Rantes/CCL5-driven herpes simplex thymidine kinase expressed by MSC infiltrating the tumor 
stroma. Preliminary experiments revealed that CCL5-expression by MSC in the tumor stroma is 
triggered by a combination of inflammatory cytokines, especially TNF-α, IL-1β and γ-IFN. Hypoxia, a 
prominent feature of growing solid tumors, was shown here not to promote CCL5-expression. 
Hypoxia-inducible factor 1α (HIF-1α) is expressed by MSC in a hypoxia-dependent manner, as 
confirmed by in vitro experiments. Thereupon, a reporter plasmid was designed that contained a 
HIF-1α-responsive promoter driving a firefly luciferase (pGL3-hypoxia-luc) or mCherry fluorescent 
protein (pGL3-HIF-Cherry). For proof of concept in this study, an in vitro model was developed by 
establishing tumor spheroids from the human hepatocellular carcinoma (HCC) cell line Huh7. Upon 
co-culture, MSC stably transfected with the pGL3-HIF-Cherry construct invaded the Huh7 spheroids 
and expressed the Cherry fluorescent protein once they had reached the hypoxic center of the 
tumor spheroid. With regards to clinical applicability and incorporation of this novel therapeutic 
concept into existing treatment regimens, an additional construct was designed such that MSC 
express a reporter or therapeutic gene using a hyperthermia-responsive promoter, namely, the 
endogenous HSP70b-promoter. It was strongly induced in MSC exposed to heat shock (42°Celsius) in 
vitro. 
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This study expands our options for the engineering of MSC to express therapeutic transgenes 
directed at the tumor microenvironment.   
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1 Introduction 
1.1 Mesenchymal Stem Cells 
Mesenchymal stem cells (MSC) have generated scientific interest in recent years. Their role in tissue 
(re-)generation has led to numerous publications highlighting their therapeutic potential in diverse 
medical specialties. What has emerged is that MSC possess unique qualities.  
MSC are defined by the International Society for Cellular Therapy as plastic-adherent cells that are 
capable of differentiation into osteoblasts, adipocytes and chondrocytes upon adequate stimulation 
in vitro, and express a set of cell surface markers, including CD105, CD73 and CD90, while 
simultaneously lacking expression of CD45, CD34, CD14 or CD11b, CD79α or CD19, as well as HLA-DR 
antigens (Casazza 2014). This combination of expressed proteins can be found on a range of cells 
and a distinctive surface marker for MSC remains to be identified (Rastegar 2010). MSC have been 
successfully isolated from almost every type of tissue, including brain, liver, blood and adipose 
tissue, mostly in the form of resident stem cells. A large source of undifferentiated MSC is found in 
the bone marrow, although MSC make up as little as 0.001-0.01% of cells (Rastegar 2010) in the 
average bone marrow aspirate. Numerous study groups have subsequently identified cell surface 
markers and cytokine receptor profiles for stem cell populations originating from diverse tissues. It 
was shown that MSC from different tissues can differ in their molecular characteristics (Lazennec 
2008, Rastegar 2010, Sivasubramaniyan 2012). What appears common is that MSC lack expression 
of major histocompatibility complex type II (MHCII)-molecules as well as co-stimulatory ligands 
CD40, CD80 and CD86 (Rastegar 2010). This aspect of MSC biology is of particular significance, as it 
renders these cells invisible to immune surveillance by circulating T-cells and thus suitable for 
allogenic transplantation without the need for immunosuppression (Le Blanc 2005, Chamberlain 
2007, Yagi 2010). Interestingly, Le Blanc et al (2005) have reported that MHCII can be detected in 
MSC lysates, suggesting that MSC possess intracellular stores of MHCII that may be mobilized and 
expressed on to the cell surface (Hagenhoff 2016).  
The ability of MSC to escape detection and elimination by the host immune system in the context of 
allogenic transplantation, has focused interest on their potential role in immunomodulation. A large 
body of reports has shed light on the often ambivalent functions of MSC in this regard. For example, 
to tie in with the aforementioned MHCII-expression, it has been established that MHCII surface 
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expression is generally γ-IFN-dependent. γ-IFN is a proinflammatory cytokine, and while low levels 
induce MHCII surface expression, high levels of γ-IFN, for example during inflammation, can 
suppress MHCII expression and may then prevent MSC from functioning as antigen-presenting cells 
(Chan 2006, Sheng 2008). Furthermore, MSC have been reported to suppress the function of both 
naïve and memory T-lymphocytes through their secretion of soluble factors (Krampera 2003, 
Rastegar 2010, Yagi 2010, Klopp 2011). This is supported by numerous publications that describe an 
immune suppressive effect of MSC in the treatment of Graft-versus-Host-Disease (GvHD) following 
allogenic stem cell transplantation (Le Blanc 2004, Le Blanc 2008, Wernicke 2011). Other groups 
have described the influence of MSC on B-lymphocytes and have shown that co-culture leads to cell 
cycle arrest and reduced expression of chemotactic cytokines in B-cells (Corcione 2006). The overall 
immunosuppressive effect of MSC is also discussed to play a major role in tumor initiation and 
preservation (Klopp 2011). 
An important trait of MSC is their innate tropism for injured tissue. Through underlying mechanisms 
that have yet to be fully understood, MSC have the ability to home to sites of injury, including 
tumors. When injected intravenously or locally in mouse models bearing injuries or tumors, MSC are 
recruited to the injured tissue with remarkable specificity. Healthy, uninjured tissue does not 
generally provide the stimuli for MSC to migrate into the tissue, however some tissue specific 
homing is seen in the heathy mouse. Fluorescently or otherwise labelled MSC, injected 
intravenously in healthy mice have been shown to accumulate in lymphatic tissue, for example 
lymphnodes, but also spleen, gut, and skin, as well as the lung. It is assumed that homing to lung 
and spleen may be mainly due to entrapment of the cells in the microvasculature, while an 
involvement of chemokine-mediated recruitment is thought to be responsible for their migration to 
the other tissues potentially as part of normal tissue homeostasis (Studeny 2004, von Luettichau 
2005, Chamberlain 2007). The molecular basis of MSC homing is thought to resemble that seen 
during leukocyte recruitment (Yagi 2010). The CXCR4-SDF1/CXCL12-has been proposed to play a role 
in MSC recruitment. Stromal-derived-factor 1 (SDF-1) is induced at sites of injury, especially in 
ischemic tissue in a HIF1-dependent manner (Ceradini 2004). The corresponding chemokine 
receptor, CXCR4, is expressed on CD34-negative bone marrow-derived progenitor cells. However, 
reports differ over the extent of CXCR4-expression on the surface of these cells, as several groups 
have reported low cell surface expression of the receptor combined with high intracellular 
expression. These findings suggest that CXCR4 is expressed on the cell surface of MSC after 
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stimulation in situations of injury (von Luettichau 2005, Chamberlain 2007, Yagi 2010). More recent 
studies suggest that MSC homing to gliomas may also be TGF-β1-dependent (Shinojima 2012).  
MSC homing has been identified in various situations of injury and malignant growth. For example, 
cardiac as well as cerebral ischemic injury can stimulate MSC to migrate towards the damaged 
tissue. Treatment of patients with myocardial infarction or middle cerebral artery infarcts in clinical 
trials has led to significantly improved outcome (Rastegar 2010). In paraplegic mouse models, MSC 
have been found to promote recovery by bridging the injury in the spinal cord and secreting growth 
factors and other paracrine factors (Hofstetter 2002). Skin defects and chronic inflammatory 
diseases such as Morbus Crohn have also been targets for treatment with MSC in experimental 
settings (Mansilla 2005, Chamberlain 2007, Rastegar 2010). 
Tumors resemble chronic wounds in certain key aspects (Dvorak 1986). During wound healing, 
cytokine crosstalk leads to the proliferation of fibroblasts, endothelial and epithelial cells, and the 
recruitment of MSC to the site of injury leads to tissue regeneration. Tumors are thought to be seen 
by the body as chronic wounds that drive continuous repair. The body reacts by providing a growth-
stimulating environment for the tumor, the tumor stroma (Dvorak 1986, Karnoub 2007, Barcellos-
de-Souza 2013). It has been shown that MSC play a key role in this process. They are recruited by 
signals sent from the tumor microenvironment, migrate towards the tumor and integrate into the 
tumor stroma (Hall 2007, Spaeth 2009, Kidd 2012). The tumor types shown to actively recruit MSC 
include gastrointestinal tumors such as colon or pancreatic cancer (Shinagawa 2010, Bao 2012, 
Shinagawa 2012, De Boeck 2013), gynecological tumors such as breast or ovarian cancer (Karnoub 
2007, Dembinski 2013), gliomas (Shinojima 2012) and melanomas (Studeny 2004, Hagenhoff 2016).   
The differentiative capacity of MSC, however, is not the only feature that renders these cells vital in 
wound healing. MSC have been shown to be involved in all three phases of wound healing: 
inflammation, proliferation and remodeling (Maxson 2012). While anti-inflammatory signaling helps 
progressing from active to healing wound in an early stage, the secretion of matrix metalloproteases 
(MMP) and growth factors such as vascular endothelial growth factor (VEGF), platelet-derived 
growth factor (PDGF) or hepatocyte growth factor (HGF) helps regulate angiogenesis and tissue 
repair (Gnecchi 2008, Maxson 2012). During formation of tumor stroma, tumor- or cancer-
associated fibroblasts (TAF or CAF) have been identified to play a central role. TAF are thought to 
originate either from the bone marrow or from tissue resident cells (Hall 2007, Spaeth 2009, Quante 
2011). Kidd et al. have distinguished two types of TAF within the tumor microenvironment: an α-
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SMA (α-smooth muscle actin) positive cell type that derives from adipose tissue, and an FAP 
(fibroblast-activating protein) and FSP (fibroblast-specific protein) positive cell type thought to 
originate from bone-marrow derived stem cells (Kidd 2012). In addition to their expression of 
fibroblast markers FSP, FAP and myofibroblast-associated proteins such as α-SMA, TAF are also 
characterized by expression of MMP-3 and SL-1, and tumor-supportive soluble factors such as IL-6, 
VEGF, HGF and TGF-β. Growth factors such as HGF, EGF and IL-6 are also thought to be secreted by 
MSC during their conversion into TAF, suggesting a role for autocrine stimulation (Spaeth 2009). In 
short, these findings suggest that TAF develop from MSC and promote tumor growth via vascular 
support, contribution to tumor stroma and immunosuppression. Another aspect of MSC or TAF in 
tumor biology is their suspected role in metastasis. MSC-secreted CCL5 was suggested to help 
promote the metastatic potential of breast cancer cells (Karnoub 2007). EMT, epithelial-
mesenchymal transition, has been linked to cancer metastasis. MSC have been shown to down-
regulate the expression of E-cadherin in favor of N-cadherin in breast cancer cells, a process that is 
essential to EMT (Klopp 2010, Klopp 2011, Hagenhoff 2016).  
The identification of a central role of MSC in tumor biology has led to their development as a tool for 
cancer therapy. Based on their tropism for tumors, MSC have been exploited as vehicles for the 
delivery of anti-cancer agents deep into tumor environments (Hagenhoff 2016). A range of 
strategies have shown efficacy in preclinical models. Studeny et al engineered MSC to constitutively 
express β-IFN, an anti-proliferative cytokine, and injected the engineered cells intravenously into 
mice bearing melanomas. As a result, the intra-tumor concentration of β-IFN that was sufficient to 
create an anti-tumor effect was achieved with tolerable serum levels of the cytokine, a clear 
advantage as compared to systemic β-IFN therapy (Studeny 2002). Sasportas et al used MSC 
expressing TRAIL (tumor necrosis factor related apoptosis inducing ligand), a cytokine that induces 
apoptosis in cancer cells, to treat mice bearing highly malignant glioblastomas (Sasportas 2009). 
Miletic et al injected MSC secreting herpes simplex virus thymidine kinase (HSV-TK) into the vicinity 
of tumors in mice (Miletic 2007). HSV-TK is capable of phosphorylating and thus activating 
ganciclovir, a prodrug that was administered later. When phosphorylated, ganciclovir is a toxic 
metabolite that induces cell death and kills surrounding cells through a bystander effect (Van Dillen 
2002). Previous work by our group focused on evaluation of MSC-based delivery of this suicide gene 
HSV-TK to solid tumors in a tissue-specific manner, such that expression would be enhanced in MSC 
that had successfully infiltrated the tumor stroma. To this end, MSC were engineered to express 
HSV-TK under the control of the Tie-2-promoter/enhancer. This allowed for a selective targeting in 
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response to the angiogenic state of the tumor stroma, as the MSC respond to angiogenic signals. 
The Tie-2 gene encodes an angiopoietin receptor tyrosine kinase that is upregulated in growing 
tumors to promote angiogenesis (Conrad 2011). A slightly different approach focused on use of the 
CCL5 promoter to drive transgene expression. As was detailed above, CCL5 is upregulated by MSC in 
the tumor stroma as the cells respond to tumor signals. The CCL5-HSV-TK engineered MSC were 
shown to infiltrate the tumor stroma, induce expression of the suicide gene and to reduce tumor 
size in mice bearing metastasized pancreatic carcinoma (Zischek 2009, Hagenhoff 2016). The CCL5 
promoter has been subsequently used in a similar experimental setting that relied on use of the 
sodium iodide symporter (NIS), derived from follicular cells of the thyroid gland, to replace the HSV-
TK suicide gene. The engineered MSC express the NIS protein once they reach the tumor stroma and 
thus allow efficient radioiodine uptake and reduced growth of hepatocellular carcinoma in mice 
(Knoop 2013). 
1.2 Tumor Stroma: Characterization 
As detailed above, Dvorak postulated in 1986 that tumors act essentially as chronic wounds (Dvorak 
1986). To date, chronic inflammation is seen as one of the main pillars of cancerogenesis (Aldinucci 
2014, Borsig 2014). This has led to increased focus on the tissue surrounding the tumor, the tumor 
stroma. The tumor microenvironment is divided into three compartments: The cancer cells 
themselves, which reside within a surrounding milieu that acts as a defensive structure with tissue 
integrity. The second component is comprised of benign cells, mainly fibroblasts, endothelial cells, 
immune cells and MSC. Finally, the extracellular matrix (ECM) is seen as the third component. The 
ECM consists of structural proteins like collagen or proteoglycans and specialized proteins like 
fibronectin and matrix-metalloproteinases (MMP), which are responsible for remodeling the ECM 
(Bremnes 2011).  
The tumor stroma is of vital importance for the progression of solid tumors. Cytokine crosstalk 
between cancer and non-malignant cells helps dictate a course towards proliferation. The switch 
from normal tissue stroma to tumor stroma is initiated by the tumor cells. Fibroblasts play a key role 
in this regard (Bremnes 2011, Borsig 2014). In normal tissues, fibroblasts are usually in a quiescent 
state. Upon disruption of the tissue equilibrium, as is the case during injury or inflammation, the 
resident fibroblasts are activated and begin secreting growth factors and producing components of 
ECM. As soon as the wound has healed, most fibroblasts undergo apoptosis (Desmouliere 1995, 
Silzle 2004). Correspondingly, tumor stroma is a blur of fibroblast activity but here the fibroblasts do 
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not undergo apoptosis, but instead develop into TAF (please refer to chapter 1.1) that continue to 
promote tumor proliferation. TAF release pro-fibrotic growth factors, such as TGF-β (transforming 
growth factor β), PDGF, FGF-2 (fibroblast growth factor 2) and VEGF. VEGF is a key player in growing 
tumors, as it helps provide an adequate oxygen supply by inducing neovascularization, and at the 
same time reinforces the process of fibroblast activation by increasing vascular permeability for 
plasma proteins such as fibrin, which in turn attracts more fibroblasts and inflammatory cells to the 
tumor site (Brown 1999, Bremnes 2011). TGF-β is thought to be an important activator of stromal 
fibroblasts. It is secreted both by cancer cells, and activated fibroblasts, in an autocrine loop that 
maintains and strengthens TGF-β-induced differentiation of fibroblasts into activated 
myofibroblasts. Ironically, while TGF-β-signaling has been linked to poor outcome in cancer, it was 
originally characterized as an anti-proliferative cytokine. One explanation for this paradox is that 
while cancer cells are able to switch off key components of the anti-proliferative TGF-β pathway, the 
tumor stroma remains responsive to TGF-β signaling. TGF-β secretion by cancer cells not only results 
in the activation of resident tissue fibroblasts, but also in the differentiation of bone marrow-derived 
MSC into TAF. In addition, cancer cell-derived TGF-β is thought to induce MMP secretion by TAF, 
which is responsible for ECM remodeling and thus enhanced invasiveness of the tumor stroma 
(Bremnes 2011, Calon 2014).  
The tumor stroma is a complex environment where cancer cells communicate with resident tissue 
cells as well as cells that have been recruited into the stroma. Communication is established by 
direct cell-cell contact and, more importantly, by secretion of soluble factors. Key players in this 
cytokine crosstalk include TGF-β, VEGF or PDGF. An active tumor stroma is associated with tumor 
growth, angiogenesis, invasiveness and metastasis.  
Previous work by our group has focused on the biology of chemokines, a class of chemotactic 
cytokines that induce the directed migration of cells. Chemokines can be produced in response to 
cytokines such as tumor necrosis factor α (TNF-α) or TGF-β. Cells that possess the necessary 
chemokine receptors can migrate along a gradient towards the site of increased chemokine 
expression. These cells include lymphocytes, macrophages, dendritic cells, MSC or resident 
parenchymal tissues. During inflammation, a set of inflammatory chemokines, such as CCL5 (CC-
ligand 5) or CCL2, helps direct leukocyte trafficking towards the site of injury. In lymphoid tissues, 
homeostatic chemokines, such as CXCL12 or CCL19, are constitutively expressed and help direct the 
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trafficking and organization of resident leukocytes (Borsig 2014). In tumors, chemokines can act as 
growth factors, they can help promote angiogenesis and have been linked to metastasis.  
1.2.1 RANTES 
The RANTES/CCL5 chemokine was first described as a chemokine expressed by T-cells. The name 
RANTES stands for “regulated on activation, normal T-cell expressed and secreted” (Von Luettichau 
1996). Over time, it has become apparent that CCL5 can be expressed by a wide range of cells, 
including macrophages, fibroblasts and MSC (Nelson 1993, Soria 2008). NF-κB is often involved in 
CCL5 up-regulation (Nelson 1993). CCL5 is a ligand for the chemokine receptors CCR1, CCR3 and 
CCR5. CCL5 has been shown to help drive the inflammatory response through recruitment of 
leukocytes. As inflammation is a hallmark of cancer, investigations focused on a potential 
involvement of CCL5 in cancerogenesis. While a role for CCL5 in breast cancer has been extensively 
investigated, other solid and hematological malignancies also show high expression profiles 
(Aldinucci 2014). In breast cancer, CCL5 is expressed by breast cancer cells, while normal breast 
epithelial duct cells show minimal expression, suggesting up-regulation of CCL5 during the process 
of malignant transformation (Soria 2008). Another group found elevated plasma levels of CCL5 in 
breast cancer patients as well as high expression in operative specimen in these patients to 
correlate with advanced and progressive disease (Niwa 2001). As a result, CCL5 may serve as a 
prognostic marker in breast cancer patients, indicating an advanced stage and progressive disease 
(Yaal-Hahoshen 2006). However, it is not only expressed by the cancer cells themselves, but also by 
MSC in the surrounding tissue (Luboshits 1999). Karnoub et al. showed that CCL5 is highly expressed 
by MSC when co-cultured with breast cancer cells in vitro and that MSC-secreted CCL5 is linked to an 
increased metastatic potential in a mouse model (Karnoub 2007). As was mentioned earlier, Zischek 
et al. were able to demonstrate CCL5-upregulation in MSC in an orthotopic mouse model of 
pancreatic cancer. Making use of this biology, MSC were equipped with a CCL5-driven fluorescent 
protein and administered intravenously three times during a period of 21 days. Fluorescent analysis 
of the tumors ex vivo showed reporter gene expression, thus showing CCL5 up-regulation in MSC 
that had infiltrated the tumor stroma (Zischek 2009).  
1.2.2 Hypoxia 
Tumor hypoxia is an important consideration for cancer therapy. It has been linked to cancer 
progression, metastasis and outcome. Oxygen diffusion is limited to about 100 to 200µm distance 
from blood vessels. As a consequence, most rapidly growing tumors show an average oxygen 
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tension of 0 to 7.5 mmHg, the equivalent of 1% O2 (Casazza 2014, Mueller 2016). Hypoxia-inducible 
factors 1α and 2α (HIF-1α and HIF-2α) can be detected in tissue sections from a range of tumors and 
especially HIF-1α is now established as a prognostic factor for poor outcome in patients with early-
stage cancers (Semenza 2009). Hypoxia has also been linked to the resistance of tumors to therapy, 
especially radiotherapy (Harrison 2002, Harada 2012).  
Hypoxia-inducible factor 1 (HIF-1) was discovered almost 30 years ago, when analysis of the 3’ 
enhancer region in the erythropoietin gene revealed a short sequence of five nucleotides, 5’-RCGTG-
3’, that was later defined as a hypoxia response element (HRE). Later, a dimeric HIF-1 transcription 
factor was found to bind to the HRE in a hypoxia-dependent manner (Goldberg 1988, Semenza 
1991). HIF-1 consists of two subunits: HIF-1α, which is induced in hypoxic conditions and HIF-1β, 
which is constitutively expressed. Under hypoxia, the two form a heterodimer that translocates into 
the nucleus, and binds to HRE in the enhancer regions of target genes that need to be regulated in a 
cellular state of low oxygen tension (Wang 1993). The mechanisms underlying hypoxic induction of 
the subunit HIF-1α are well-described and have been summarized by Semenza as follows: Under 
normoxic conditions, the prolyl hydroxylase PHD2, which uses O2 as a substrate, hydroxylates a 
proline residue and thus exposes HIF1-α to the von-Hippel-Lindau (vHL) protein, which binds to the 
hydroxylated proline and marks HIF-1α for ubiquitination and proteosomal degradation. An 
additional O2-dependent mechanism for inhibiting HIF-1α during normoxia, is the active 
hydroxylation of an asparaginyl residue of factor-inhibiting HIF-1 (FIH-1), which undermines co-
activation through p300. HIF-1α can also be induced chemically through iron chelators or chemicals 
like cobalt chloride, that interfere with a divalent iron ion (Fe2+) in the catalytic center of 
hydroxylases, which leads to intracellular accumulation of HIF-1α (Semenza 2012). Downstream 
target genes of HIF-1 are generally related to glucose metabolism, angiogenesis, proliferation, pH 
regulation and, in cancerous cells, genomic instability, radiotherapy resistance, immortalization, 
immune evasion and metastasis (Semenza 2009). The task of HIF-1 is to help the cell adapt to 
hypoxic conditions, which includes switching from oxidative to glycolytic metabolism in order to 
produce energy in the form of adenosine triphosphate (ATP). HIF-1 induces the expression of 
pyruvate dehydrogenase kinase I (PDKI). This enzyme is capable of inactivating pyruvate 
dehydrogenase, an enzyme that catalyzes the irreversible conversion of pyruvate to acetyl-CoA, 
such that pyruvate resulting from glycolysis is not fed into the citrate cycle, but instead converted to 
lactate (Kim 2006, Papandreou 2006). Another player in this scenario is lactate dehydrogenase A 
(LDHA), the enzyme catalyzing the aforementioned conversion of pyruvate to lactate (Semenza 
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1996). Finally, mitochondrial autophagy is also induced by HIF-1 and helps to prevent accumulation 
of reactive oxygen species (Zhang 2008, Bellot 2009). Another important step in adapting to hypoxia 
is to reduce proliferation and HIF-1 helps to mediate G1 cell cycle arrest (Semenza 2013). In order to 
improve oxygen supply, HIF-1 promotes angiogenesis. VEGF, as was explained earlier, assumes a 
pivotal role in angiogenesis and is also induced via HIF-1-activation (Forsythe 1996).  
Oxygen tension varies greatly, not only between cancer types, but also between cells of the same 
tumor. There is growing evidence for a metabolic symbiosis between those two types of cancer 
cells, where hypoxic cells accumulate lactate as a waste product of glycolysis, which is in turn 
utilized by normoxic cells to fire the respiratory chain (Nakajima 2013, Semenza 2013). HIF-1 is 
assumed to be an important manipulator in this scenario. It induces gene expression of glycolytic 
enzymes, lactate dehydrogenase A (LDHA) and monocarboxylate transporter 4 (MCT4) in hypoxic 
cancer cells. Thus, HIF-1 is one of the key players not only in cancer cells themselves, but also in the 
tumor microenvironment.  
Endothelial cells are the principal performers in angiogenesis. The crucial factor initiating migration 
towards hypoxic areas and promoting the formation of new blood vessels, is a gradient of the 
growth factors of the VEGF family. VEGF is strongly induced by HIF-1. The over-production of 
angiogenic factors like VEGF in the stroma of growing tumors can lead to excessive vessel sprouting 
that can end with a faulty vasculature, where the basement membranes are incoherent, tight 
junctions are lacking, and supporting pericytes detach from the endothelium (Casazza 2014). 
Consequently, vessel leakage leads to impaired oxygen supply, high pressure on the surrounding 
tissue resulting in insufficient delivery of oxygen and other nutrients to the tumor cells (Carmeliet 
2011). The role of bone-marrow derived progenitor cells such as MSC in tumor neovascularization 
has been discussed controversially in the past. What has been established is that MSC have the 
potential to be mobilized out of their niche in the bone marrow by a range of soluble factors, for 
example VEGF or SDF-1, via a HIF-1-dependent mechanism (Ceradini 2004, Spring 2005, Kerbel 
2008). Hämmerling et al describe a multistep process involved in the recruitment of bone marrow-
derived MSC, with CC chemokines such as CCL2 or CCL5 attracting circulating progenitor cells to the 
tumor stroma. These chemokines are described as being secreted by local endothelial cells in an 
auto- and paracrine fashion. Once incorporated into the tumor stroma, the bone marrow-derived 
cells begin to secret growth factors like VEGF, PDGF or EGF themselves. Endothelial cells possess 
receptors for both growth factors and the chemokines CCL2 and CCL5, so that a self-servicing loop is 
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being established, which launches a so-called angiogenic switch leading to massive 
neovascularization (Hämmerling 2006). Whether MSC, once they have been incorporated into the 
tumor stroma, have the capacity to differentiate into endothelial cells themselves remains 
debatable. Beckermann et al report no significant differentiation of MSC exposed to endothelial cell 
medium containing VEGF into endothelial cells in vitro and in vivo. However, MSC incorporate into 
the endothelium of tumor blood vessels in a VEGF-dependent fashion and vessel architecture also 
includes stabilizing cells such as pericytes and smooth muscle cells (Beckermann 2008). Consistent 
reports suggest that bone marrow-derived MSC enhance functional vasculature by differentiating 
into pericytes (Au 2008).  
However, as described in chapter 1.1., bone marrow-derived MSC that are recruited into the tumor 
stroma not only serve to promote angiogenesis, but also make up key components of the tumor 
microenvironment in the form of TAF, tumor-associated fibroblasts. Once they enter the tumor 
stroma, the mechanisms that induce the adaption of a TAF-like phenotype are not completely 
understood. Several groups, however, have shown that HIF-1-dependent lysosomal degradation of 
Calveolin-1 is one of the key components (Martinez-Outschoorn 2010, Casazza 2014, Hagenhoff 
2016).  
Tumor hypoxia, or more specifically, positive staining for HIF-1 proteins in tissue sections of tumor 
specimen, has been identified as a prognostic factor for increased invasiveness, advanced stage of 
disease and poor outcome in general (Semenza 2009). Increased stage of disease refers to the 
degree of local progression as well as metastasis to distant organs. HIF-1 protein has been identified 
as a supporting factor of metastasis in every step of the way. Epithelial to mesenchymal transition 
(EMT) describes the process of cells losing their polarity and acquiring a mesenchymal phenotype, 
which enables them to break out of a tight cell compound. Several HIF-1-target genes like SNAIL1 or 
TWIST are transcriptional repressors of E-cadherin, a transmembrane protein that controls cell-cell 
adhesions and is required for EMT (Imai 2003, Yang 2008). Degradation of ECM (please refer to 
chapter 1.2) and disruption of the basement membrane by matrix metalloproteinases (MMP) are 
prerequisites for an invasive cancer phenotype. MMP-2 and MT1-MMP are up-regulated in hypoxia 
via a HIF-1-mediated pathway (Krishnamachary 2003, Muñoz-Nájar 2006). Intravasation of cancer 
cells correlates with increased permeability of the tumor vasculature, mediated by the HIF-1 target 
genes VEGF, MMP-1 and MMP-2 (Lu 2010). Finally, tumor hypoxia poses a risk for resistance to 
radio- and chemotherapy. This is partly explained by the fact that the presence of oxygen increases 
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the amount of free radicals that result from DNA strain breaks. Furthermore, hypoxia and acidity 
impair the function of DNA mismatch repair, which allows for mutations that can eventually lead to 
resistance to therapy (Harrison 2002). Now, Harada et al were able to show that deeply hypoxic 
cancer cells at the periphery of a tumor that showed no signs of HIF-1-expression prior to radiation, 
acquire HIF-1-activity after radiation and subsequently translocate towards blood vessels, thus 
securing oxygen and nutrient supply required for local recurrence (Harada 2012). These findings 
suggest that severe tumor hypoxia favors an aggressive and resilient cancer type and is thus worth 
investigating as a target of cancer therapy. 
1.2.3 Heat Shock Proteins and Hyperthermia 
The potential importance of heat shock proteins and hyperthermia In the context of resistance of 
tumors towards radio- and chemotherapy has become a major focus in cancer research over the last 
years. Heat shock proteins (HSP) are highly conserved proteins involved in the cellular stress 
response and are either constitutively expressed, or are induced by physiological and environmental 
stress. In mammalian cells, four families of HSP have been identified that differ in molecular weight. 
They are designated as HSP90, HSP70, HSP60 and small HSP, a group ranging from 15 to 30 kDa that 
includes HSP27 (Jego 2010). The main task of the HSP is to save the cell from damage caused by 
misfolded proteins that result from cellular stress. The stress factors identified include 
hyperthermia, cellular energy depletion, or shifts in ion and gas concentrations (Feder 1999). The 
name “heat shock protein” originates from their random discovery by Ritossa and colleagues in the 
1960s, when accidental over-heating of Drosophila in the laboratory caused a distinct puffing 
pattern in chromosomes (Ritossa 1962). Since then, decades of research have shed light on the 
biology of the heat shock response and thus the cellular response to environmental insult. HSP are 
strongly cytoprotective by acting as chaperones within the cell for misguided proteins. At certain 
temperatures, proteins begin to denature, which means they lose their tertiary or quaternary 
structure, and become a threat to the cell. HSP, which typically exhibit a peptide binding site and an 
ATP-binding site, are able to refold mis- or defolded proteins, or promote their degradation if 
necessary, and prevent or dissolve the aggregation of proteins and escort proteins on their way for 
instance to the cell surface (Lindquist 1988, Feder 1999, Garrido 2001). In addition, HSP are directly 
and indirectly involved in apoptosis: HSP70, the best studied HSP family, is involved in several steps 
of the apoptotic cascade, mostly showing inhibitory effects on several pro-apoptotic factors, such as 
apoptotic protease activating factor 1 (Apaf-1) and apoptosis-inducing factor (AIF) (Garrido 2001, 
Garrido 2006). However, HSP are not only restricted to the cytosol, they can also be encountered as 
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membrane-bound, or in the extracellular space. Here, they show immunogenic properties and 
function as chaperones to antigenic peptides that are processed, incorporated into MHC class I 
molecules and presented to natural killer cells and dendritic cells (Noessner 2002, Srivastava 2002, 
Schmitt 2007). Furthermore, Multhoff et al were able to show that heat shock-induced 
overexpression of HSP70 on tumor cell surfaces leads to activation of CD94-expressing natural killer 
cells that subsequently release granzyme B and induce apoptosis of the tumor cells (Multhoff 2007). 
The up-regulation of HSP is seen in some cancers, while their healthy equivalent tissue shows little 
or no expression. These levels can be further increased by additional stress factors, such as 
hyperthermia, oxidative stress, death receptor ligation or, interestingly, radiation or chemotherapy 
(Jego 2010). The general assumption is that HSP help tumors survive in adverse environments. 
Patients undergoing chemo- or radiation therapy for the treatment of solid tumors have been 
shown to profit from local hyperthermia, in that it reduces both local recurrence as well as distant 
metastasis (Issels 2010). As reviewed by Jolesch et al, this is partly due to an improved immune 
response mediated by heat-induced expression of HSP70 (Jolesch 2011).  
Hyperthermia treatment has also been shown to impair DNA repair on multiple levels. While it 
induces DNA damage on its own, it  also affects DNA damage signaling and cell cycle checkpoint 
activation (Oei 2015). Thus, hyperthermia has been shown to provide a synergistic effect with 
certain chemotherapeutic drugs, such as alkylating agents and anthracyclines (Behrouzkia 2016, 
Seifert 2016). Mild hyperthermia of 40-41°C increases blood perfusion and thus access of anti-
cancer drugs to the tumor microenvironment, if applied locally. Increased blood perfusion keeps the 
tumor microenvironment richly oxygenated, which is known to help radiation therapy (Wust 2002). 
These examples show that while hyperthermia on its own presents only limited treatment options, 
its effect combined with that of standard chemo- or radiation therapy protocols holds promise.  
To create local hyperthermia in a tumor, energy needs to be deposited precisely and deeply within 
the body. Emerging technologies that have been used to achieve this include focused ultra-sound - 
the only non-invasive option - as well as minimally invasive placement of radio frequency electrodes. 
To control local hyperthermia, magnetic resonance (MR) temperature mapping now represents the 
method of choice (Rome 2005). 
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1.3 Hepatocellular Carcinoma 
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, and the most lethal 
malignancy after lung and stomach cancers (Hernandez-Gea 2013). According to the World Health 
Organization’s (WHO) world cancer report of 2014, primary liver cancer is the fifth most common 
cancer in men, and the ninth most common cancer in women, and accounts for the second highest 
number of cancer-related deaths worldwide. The vast majority of HCC cases are reported in 
developing countries of Eastern Asia and sub-Saharan Africa, with Southern Europe and North 
America showing intermediate incidence (WHO 2014). In areas of high incidence, HCC is diagnosed 
mostly in patients around 50 to 60 years of age, as opposed to areas of low incidence, where the 
mean age of diagnosis is as high as 75 years (El-Serag 2012). Prognosis is poor and mirrored in an 
overall five-year survival below 15%, that improves significantly to over 50% in patients with early-
stage diagnosis eligible for surgical treatment (El-Serag 2011, WHO 2014). In Germany, according to 
the Robert-Koch-Institute’s (RKI) cancer report of 2013, roughly 8000 patients are newly diagnosed 
with primary liver cancer per year, with 65% of them presenting with HCC and 25% with 
cholangiocellular carcinoma (Robert-Koch-Institut 2013).  
The predominant risk factor for development of HCC is liver cirrhosis, with more than 80% of HCC 
patients presenting with cirrhotic liver disease at the time of diagnosis. Once cirrhosis has become 
manifest, the overall risk to develop HCC within five years is up to 30% (Fattovich 2004). As reviewed 
by El-Serag in recent years, chronic hepatitis B (HBV) and hepatitis C (HCV) virus infection can be 
made out as the underlying cause in more than 80% of HCC patients and geographic distribution of 
HBV and HCV infection is congruent with that of HCC. Other causes of liver cirrhosis and 
consequently HCC include chronic alcohol abuse and non-alcoholic fatty liver disease, as well as 
some hereditary diseases such as hemochromatosis, Morbus Wilson, autoimmune hepatitis and 
alpha-1-antytrypsine-deficiency (Farazi 2006). The only notable risk factor for HCC without 
underlying cirrhosis is exposure to aflatoxin-B1, produced by Aspergillus flavus fungus, which is 
associated with a carcinogenic p53-mutation (Bressac 1991). 
The high mortality in HCC is a result of several factors. Curative treatment options in HCC therapy 
are scarce and largely limited to early stages, whereas most patients presenting with HCC have 
already progressed to advanced stages. To date, with no biomarkers available, diagnosis in early 
stages relies on frequent and continuous screening of high-risk patients with liver cirrhosis, a 
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process that requires extensive funding and high patient compliance. Once a cancerous lesion is 
suspected, further diagnosis includes contrast-enhanced cross-sectional imaging and biopsy.  
Treatment options for HCC are evaluated according to local and systemic tumor progress, balanced 
with remaining liver function (Bruix 2005). In patients with limited local disease and light to 
moderate liver disease (Child A or B), surgical resection of the tumor represents the best option, if 
the remaining liver is thought to be functional enough. If that is not the case, and the patient meets 
certain criteria, they might be eligible for liver transplantation (El-Serag 2011). However, stalling 
tumor progress until a suitable organ becomes available is vital for treatment success. Common 
systemic chemotherapeutic agents have proven ineffective in HCC therapy, or contraindicated due 
to poor liver function. Local ablation techniques have been established that are able to restrain 
tumor progress in order to either prolong survival in intermediate stages or to downsize to an early 
stage that allows for curative therapeutic approaches. These techniques include radiofrequency 
ablation, local intraarterial injection of ethanol and, most importantly, transarterial 
chemoembolization (TACE) (Llovet 2002, Bruix 2004). For patients with advanced stage HCC, oral 
chemotherapy with tyrosine kinase inhibitor sorafenib is the treatment of choice and has been 
shown to prolong survival (Llovet 2008, Villanueva 2011).  
As is the case with various types of cancer, the tumor microenvironment is of utmost importance in 
formation and progression of HCC, which is a multistage process. HBV or HCV infection as well as 
long-term alcohol abuse and non-alcoholic fatty liver disease pose chronic insults for liver 
parenchyma, which lead to persistent cycles of necrosis, inflammation and regeneration. In 
response to liver injury, hepatic parenchyma is activated, mainly in the form of stellate cells. These 
begin to acquire a myofibroblast phenotype, produce components of ECM and secrete growth 
factors triggering angiogenesis and fibrosis, much like the afore-mentioned tumor-associated 
fibroblasts (TAF). This stromal disruption is capable of promoting genetic mutations, which later 
malignantly transform into early manifestations of HCC (Thorgeirsson 2002, Campbell 2005, Baffy 
2012). All in all, hepatocarcinogenesis is a compilation of diverse aetiologies that involve similar 
molecular mechanisms: p53-mutation is seen in HBV and HCV infection as well as aflatoxin B1 
exposure, while chronic inflammation is the common ground of viral hepatitis, lifestyle-induced liver 
injury like alcoholic cirrhosis and non-alcoholic fatty liver disease as well as hereditary metabolic 
disorders (Farazi 2006, Hernandez-Gea 2013). 
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In light of limited treatment options in HCC, that are often a result of underlying liver disease 
preventing effective therapy as well as promoting new tumor growth after success of treatment, it is 
necessary to find new therapeutic targets. An overwhelming number of HCC develop on the ground 
of chronic inflammation, therefore targeted therapies pointing at the tumor microenvironment in 
primary liver cancer have become an area of scientific focus. This has led to choosing HCC as a 
tumor model in this study, with the goal to find new treatment options in order to stall tumor 
growth and to allow for surgical intervention or transplantation. 
1.4 Aim of this study 
As detailed above, bone-marrow derived MSC possess an innate tropism for injured or inflamed 
tissue, which has sparked scientific interest in their role as agents in cancer therapy. Previous work 
by our group has shown that the adoptive administration of MSC engineered to express a 
therapeutic gene under the control of tissue-specific promoters is a valid approach to treat 
experimental HCC. It has been demonstrated that the CCL5-promoter is up-regulated by MSC 
invading the tumor stroma and thus can be used to help enhance tumor selective transgene 
expression in response to the inflammatory milieu within the tumor setting. One aim of this study 
was to better characterize the activation of CCL5 in this environment, but in addition, to explore 
other potential means of focusing transgene expression in the context of malignant tissue using 
various engineered versions of MSC. The general goal was to help create new potential angles for 
attacking the tumor, and potentially allow a wider range of tumor entities to be included in this 
therapeutic approach, and at the same time, reduce potential side effects of MSCs that are recruited 
to normal tissues. Thus, under the precondition of limiting damage to non-malignant tissue, the 
following targeting strategies were examined: 
Tumor hypoxia was investigated in this study as a potential means to trigger transgene induction in 
engineered MSC. We hypothesized that MSC invading the tumor stroma should respond to hypoxia. 
MSC engineered with a gene controlled by a hypoxia-sensitive promoter should be able to induce 
expression of the transgene once they have reached the hypoxic areas of the tumor 
microenvironment. The potential feasibility of this approach was tested with the help of an in vitro 
model of hepatocellular carcinoma.  
Finally, we sought to evaluate the potential activation of transgene expression in MSC within tumors 
using externally applied processes. To this end, we examined whether MSC could activate transgene 
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expression in response to hyperthermic treatment, similar to that currently used for hyperthermic 
adjuvant therapy. If so, cancer patients undergoing hyperthermia treatment of afflicted body 
regions could in theory be treated with MSC engineered to express therapeutic genes under the 
control of heat-sensitive promoters.  
1.5 Design of this study 
To help address the specific aims of this study, the following experimental steps were performed:  
• Reporter constructs containing firefly luciferase were designed with the respective 
promoters in order to examine expression of CCL5, HIF-1 and HSP70b by MSC under various 
experimental conditions in vitro. Induced CCL5 expression was further tested in MSC in 
response to various inflammatory cytokines, while HIF-1 and HSP70b-mediated transgene 
expression was analyzed by adjusting cell culture conditions to hypoxia or hyperthermia, 
respectively. 
• Reporter constructs containing Cherry fluorescent protein were designed with hypoxia-
responsive and heat shock-responsive promoters in order to examine expression by MSC 
using fluorescent microscopy.  
• A spheroid model was established using the Huh7 cell line in order to study hepatocellular 
carcinoma in vitro. It was further used to develop an invasion assay as a means to examine 
whether bone-marrow derived MSC invaded the tumor spheroids in vitro. 
• Immortalized, bone-marrow derived MSC were stably transfected with a reporter construct 
containing Cherry fluorescent protein under the control of a hypoxia-sensitive promoter.  
• These stably transfected MSC were used in an invasion assay with Huh7 spheroids to 
demonstrate activation of a hypoxia-sensitive reporter gene within the hypoxic areas of the 
spheroid.  
17 
 
 
2 Materials and Methods 
2.1 Materials 
2.1.1  Cell Culture 
2.1.1.1 Medias and supplements 
Media  
DMEM Life Technologies, Carlsbad 
RPMI 1640 Life Technologies, Carlsbad 
HAM-F12 Life Technologies, Carlsbad 
OptiMEM Life Technologies, Carlsbad 
 
Supplements  
Fetal calf serum (FCS) Biochrom AG, Berlin 
Human serum PAA Laboratories, Pasching 
Penicillin/Streptomycin (P/S), 100x PAA Laboratories, Pasching 
Platelet concentrate Blood bank, Klinikum Schwabing, München 
Na-Heparin Ratiopharm, Ulm 
Blasticidin S HCL Life Technologies, Carlsbad 
  
 
Others  
Dimethylsulfoxide (DMSO) Merck, Darmstadt 
Dulbecco’s PBS (no Ca2+ or Mg2+), 1x/10x PAA Laboratories, Pasching 
Trypan blue Sigma Aldrich, Taufkirchen 
Trypsin-EDTA in PBS, 1x PAA Laboratories, Pasching 
  
 
2.1.1.2 Cell lines and primary cells 
Cell line Comments Media Supplements Source 
L87 Immortalized (SV40) 
Mesenchymal Stem Cells 
(human bone marrow) 
Thalmeier et al, 1994 
RPMI 1640 10% FCS 
1% P/S 
Institut für 
Pathologie, LMU 
Munich 
Alex-2 Immortalized (SV40) 
Mesenchymal Stem Cells 
(human bone marrow) 
DMEM 10% FCS 
1% P/S 
Alexandra 
Wechselberger, in-
house 
Huh7 Hepatocellular Carcinoma  DMEM/HAM-
F12 (1:1) 
10% FCS 
1% P/S 
AG Spitzweg, LMU 
Munich 
hBMSC Mesenchymal stem cells DMEM 1000IE Na- Deutsche 
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(human bone marrow), 
isolated according to 
standard protocol for plastic 
adherence (Alexandra 
Wechselberger) 
Heparin 
5% platelet 
concentrate 
1% P/S 
10% human 
serum 
Knochenmarkspende 
Bayern (DKB), 
Gauting 
 
2.1.2 Bacteria 
Type Genotype Source 
E.coli DH5α supE44, ΔlacU169 (Ф80 lacZΔM15) hsdR17 
recA1 endA1 gyrA96 thi-1, relA1 
In-house 
E.coli One Shot® 
Mach1™-T1R 
F-φ80(lacZ)∆M15 ∆lacX74 hsdR(rκ-mκ+) 
∆recA1398 endA1 tonA 
Life Technologies, Carlsbad 
 
2.1.3 Buffers and solutions 
If not stated otherwise, volume percentage specifications are referring to ultra-pure H2O. 
2.1.3.1 Western blot 
Prepared in-house  
Ammoniumpersulfate (APS) 10% APS w/v 
Blocking solution 5% skim milk powder (w/v) in TBST 
Electrophoresis buffer 1.9M Glycine 
0.25M Tris 
1% SDS (w/v) 
Laemmli Buffer 3x 150mM Tris/HCl, pH 6.8 (rt) 
30% Glycerine (v/v) 
6% SDS (w/v) 
0.3% bromphenol blue (w/v) 
7.5% β-mercaptoethanol (v/v) 
Sodiumdodecylsulfate (SDS), 10% 10% SDS (w/v) 
Tris, 1M, pH 6.8 1M Tris, pH 6.8 (rt) 
Tris 1.5M, pH 8.8 1.5M Tris, pH 8.8 (rt) 
Tris-buffered saline (TBS), 10x 1.5M NaCl 
100mM Tris 
10mM NaN3 
Tris-buffered saline with Tween (TBST) 0.05% Tween20 (v/v) in 1x TBS 
 
Commercially available  
Acrylamide/Bisacrylamide solution, 30% Roth, Karlsruhe 
ECL-substrate for western blot Pierce, Rockford 
NuPAGE LDS sample buffer, 4x Life Technologies, Carlsbad 
NuPAGE transfer buffer, 20x Life Technologies, Carlsbad 
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RIPA buffer  
Tris/HCl pH 7.4 50mM 
NaCl 150mM 
EDTA 1mM 
Triton X 100 1% 
Natriumorthovanadat 1% 
SDS 0.1% 
CoCl2 1mM 
Protease inhibitor 1 tablet/50ml 
 
Separation gels  
1.5M Tris, pH 8.8 5ml 
10% SDS 200µl 
10% APS 200µl 
Tetramethylethylendiamine (TEMED) 20µl 
Acrylamide/Bisacrylamide mix, 30% 5.3ml (8%), 4.0ml (6%), 3.3ml (5%) 
H2O Ad 20ml 
 
2.1.3.2 Molecular biology 
Prepared in-house  
Loading buffer, 6x 0.25% Bromphenol blue (w/v) 
0.25% Xylen-Cyanol FF (w/v) 
30% Glycerin (w/v) 
Tris-borate-EDTA (TBE) buffer, 1x 90mM Tris 
2mM boric acid 
0.01M EDTA 
pH 8.0 (rt) 
 
Commercially available  
DNA restriction enzyme buffers, 10x NEB, Ipswich 
dNTP Set Thermo Fisher Scientific, Waltham 
Phusion HF buffer for Phusion polymerase, 5x NEB, Ipswich 
UltraPure Agarose Life Technologies, Carlsbad 
 
2.1.3.3 Microbiology 
Prepared in-house  
Agar, 2x 3% Agar (w/v) 
(autoclaved) 
Ampicillin solution 50 mg/ml Ampicillin (in 70% ethanol, w/v) 
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CaCl2 solution 60mM CaCl2 
15% Glycerin (v/v) 
10mM PIPES (piperazine-N,N′-bis(2-
ethanesulfonic acid), pH 7 (rt) 
(sterile filtered) 
Freezing medium, 10x 132.3 mM KH2PO4 
21 mM Sodiumcitrate 
3.7 mM MgSO4*7 H2O 
68.1 mM (NH)2SO4 
459.3 mM K2HPO4*3 H2O 
35.2% Glycerin (w/v) 
(autoclaved) 
LB medium 2% Bacto Tryptone (w/v) 
342 mM NaCl 
1% yeast extract (w/v) 
pH 7.2-7.3 (rt)  
(autoclaved) 
 
2.1.3.4 ELISA 
Assay buffer 1% BSA (in 1x PBS, w/v, prepared in-house) 
OptEIA substrate solution for ELISA Commercially available; BD Biosciences, Bedford 
PBS, 20x 2.74M NaCl 
129.2 mM Na2HPO4 * 2 H2O 
54mM KCl 
29.4mM KH2PO4 
Wash buffer 0.05% Tween20 (in 1x PBS, v/v) 
 
2.1.3.5 Histology and immunohistology 
Vectamount mounting medium (DAPI) Vector laboratories, Burlingame 
Shandon Formal-Fixx formalin Thermo Fisher Scientific, Waltham 
 
2.1.4 Antibodies 
Antibody Source Application 
Alexa Fluor® 594 Donkey Anti-Mouse IgG Life Technologies, Carlsbad Immunofluorescence 
Anti-Pimonidazole (mouse IgG1) Hypoxiprobe, Burlington Immunofluorescence 
Purified Mouse Anti-Human HIF-1α 
(mouse IgG1) 
BD Biosciences, Franklin Lakes Western Blot 
 
2.1.5 Enzymes 
Restriction enzymes BamHI, BglII NEB, Ipswich 
Phusion polymerase NEB, Ipswich 
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Alkaline phosphatase NEB, Ipswich 
T4 DNA Ligase NEB, Ipswich 
 
2.1.6 Human recombinant proteins 
γ-IFN PeproTech, Hamburg 
IL1-β PeproTech, Hamburg 
IL-6 PeproTech, Hamburg 
IL-10 PeproTech, Hamburg 
TGF-β1 PeproTech, Hamburg 
TNF-α PeproTech, Hamburg 
VEGF PeproTech, Hamburg 
Wnt5α R&D Systems, Minneapolis 
 
2.1.7 Size standards for electrophoresis 
1 kb DNA ladder Life Technologies, Carlsbad 
MagicMarkTMXP western protein standard Life Technologies, Carlsbad 
 
2.1.8 Primers 
For PCR primers used in the context of recombinational cloning, please refer to table 3 in chapter 
2.2.3.2 on page 36. All primers were designed using the Clone Manager software and produced by 
Life Technologies. 
2.1.9 Plasmids and vectors 
Plasmid Comments Resistance 
gene 
Source Application 
pCMV-Bsd Contains a 
blasticidin 
resistance gene 
driven by a CMV-
promoter 
inbetween two 
multiple cloning 
sites 
Ampicillin Life Technologies, 
Carlsbad 
Blasticidin 
resistance for 
pGL3-hypoxia-
luc 
PGL3-Basic Contains a 
multiple cloning 
site followed by 
firefly luciferase 
Ampicillin Promega Cloning of 
pGL3-HSE and 
pGL3-HSP70b 
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pN3-BAR-Gluc Contains Gaussia 
luciferase 
Ampicillin Anke Fischer, 
Department of 
Clinical 
Biochemistry, LMU 
Munich, AG Nelson 
Template for 
amplification 
of Gaussia 
luciferase 
pCAG-Kosak-Cherry Contains mCherry 
fluorescent 
protein 
Ampicillin Dr. Rosemann, 
Helmholtz Center 
Munich, German 
Research Center for 
Environmental 
Health, Germany 
Template for 
amplification 
of mCherry 
fluorescent 
protein 
PGL3-RFL PGL3-Basic 
(Promega) vector 
that carries a CCL5 
promoter (Rantes 
Full Length) in the 
multiple cloning 
site 
Ampicillin Christoph Zischek, 
Department of 
Clinical 
Biochemistry, LMU 
Munich, AG Nelson 
Transient 
transfections 
of MSC 
PGL3-RaPro-TK PGL3-Basic 
(Promega) vector 
that carries a CCL5 
promoter driving 
thymidine kinase 
Ampicillin Christoph Zischek, 
Department of 
Clinical 
Biochemistry, LMU 
Munich, 
AG Nelson 
Template for 
amplification 
of thymidine 
kinase 
PGL3-6xHRE-tk PGL3-Basic 
(Promega) vector 
that carries a 
hypoxia-
responsive 
promoter in the 
multiple cloning 
site. 
Ampicillin Prof. Dr. Grässer, 
Universitätsklinikum 
des Saarlandes, 
Homburg, 
Germany) 
Transient 
transfections 
of MSC; 
Template for 
amplification 
of 6xHRE-tk 
pHSE-SEAP Contains secreted 
alkaline 
phosphatase 
(SEAP) controlled 
by three tandem 
copies of HSE 
consensus 
sequence fused to 
a TATA-like 
promoter. 
Ampicillin Clontech (provided 
by Prof. Manfred 
Ogris, Department 
of Pharmacy, LMU 
Munich) 
HSE-promoter 
for pGL3-HSE 
PGL3-HSE PGL3-Basic 
(Promega) that 
carries the HSE-
promoter in the 
multiple cloning 
site 
Ampicillin Sylke Rohrer, 
Department of 
Clinical 
Biochemistry, LMU 
Munich, 
AG Nelson 
Transient 
transfections 
of MSC; 
Template for 
amplification 
of HSE 
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pHSP70b-SEAP Contains secreted 
alkaline 
phosphatase 
(SEAP) controlled 
by the 
endogenous 
HSP70b promoter 
Ampicillin Prof. Manfred Ogris, 
Department of 
Pharmacy, LMU 
Munich) 
HSP70b-
promoter for 
pGL3-HSP70b 
PGL3-HSP70b PGL3-Basic 
(Promega) that 
carries the 
HSP70b-promoter 
in the multiple 
cloning site 
Ampicillin Sylke Rohrer, 
Department of 
Clinical 
Biochemistry, LMU 
Munich, 
AG Nelson 
Transient 
transfections 
of MSC; 
Template for 
amplification 
of HSP70b 
pcDNA6.2PLITRBlasti-
Dest 
pcDNA-vector that 
carries two ITR-
sites for 
transposition, 
attR1 and attR2 
sites for 
recombination 
with a ccdB-gene 
in between, as 
well as a 
blasticidin 
resistance gene 
Ampicillin Carsten Jäckel, 
Department of 
Clinical 
Biochemistry, LMU 
Munich, 
AG Nelson 
Destination 
vector for all 
Multisite 
Gateway 
cloning 
projects in this 
study 
 
2.1.10 Kits 
DuoSet CCl5 ELISA development kit R&D Systems, Minneapolis 
Endofree Plasmid Maxi kit Qiagen, Hilden 
Innuprep Plasmid Mini kit Analytik Jena, Jena 
MultiSite Gateway Pro Plus kit Qiagen, Hilden 
Quant-it DNA assay kit, broad range Life Technologies, Carlsbad 
Quant-it DNA assay kit, high sensitivity Life Technologies, Carlsbad 
 
2.1.11 Other laboratory equipment 
CM3000 cryotome Leica, Wetzlar 
Developing machine for autoradiography films Agfa, Morsel 
E.coli Pulser Bio-Rad, Hercules 
Electroporator (for cell-culture use) Bio-Rad, Hercules 
Fluorescence activated cell scanner/sorter 
FACSAriaIII 
BD Biosciences, Franklin Lakes 
Fluorometer Qubit Life Technologies, Carlsbad 
Inverted fluorescence microscope DMIL 
Photo camera for Leica DMIL 
Leica, Wetzlar 
Jenoptik, Jena 
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PCR cycler Eppendorf, Hamburg 
 
2.1.12 Chemicals 
Aqua ad injectabilia Braun, Melsungen 
EDTA (ethylenediaminetetraacetic acid) Merck, Darmstadt 
EGTA (ethyleneglycoltetraacetic acid) Sigma-Aldrich, Taufkirchen 
Ethanol Merck, Darmstadt 
Ethidiumbromide 1% Merck, Darmstadt 
Glycerin AppliChem, Darmstadt 
Isopropanol Roth, Karlsruhe 
Methanol Merck, Darmstadt 
TRIS (trishydroxymethylaminomethane) Merck, Darmstadt 
β-Mercaptoethanol Roth, Karlsruhe 
 
2.1.13 Disposables 
96-well microtiter plate, flat bottom TPP AG. Trasadingen 
96-well ELISA Maxisorb plate Nunc, Roskilde 
4mm electroporation cuvettes PeqLab, Erlangen 
Amersham Hyperfilm ECL autoradiography film GE Healthcare, Uppsala 
Cell culture dishes (3cm, 6cm, 10cm) TPP AG. Trasadingen 
Cell culture flasks (75cm2, 150cm2) TPP AG. Trasadingen 
Cell scrapers TPP AG. Trasadingen 
Falcon tubes (15ml, 50ml) BD Bioscience, Heidelberg 
Pipette tips Greiner Bio-One, Kremsmünster 
Reaction tubes (0.5ml, 1.5ml, 2ml) Eppendorf, Hamburg 
Serological pipettes TPP AG. Trasadingen 
Superfrost Ultra Plus adhesion slides Thermo Fisher Scientific, Waltham 
 
2.1.14 Software 
Clone Manager (PCR primer design) Scientific & Educational Software, Morrisville 
FlowJo (FACS data analysis) TreeStar Inc., Ashland 
Prism 6 (graphic program, statistical analysis) GraphPad Software, La Jolla 
ProgRes Capture (imaging at Leica DLIM) Jenoptik, Jena 
SnapGene Viewer (plasmid map design) GSL Biotech LLC, Chicago  
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2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Day-to-day handling of cells 
All cells indicated as grown under normoxic conditions have been kept in incubators set to 37°C, 
21% O2 and 5% CO2. For hypoxic conditions, an incubator was used that allowed to adjust the 
oxygen level by insufflation of a gaseous mixture of 95% N2 and 5% CO2. For all in vitro experiments 
that required hypoxic conditions, the oxygen level was set to 2%. Alternatively, cells were incubated 
in the normoxic incubator, but under the influence of CoCl2, an inorganic compound, that is able to 
prevent HIF1α-degradation and thus simulates cellular hypoxia. For these in vitro experiments, CoCl2 
was added to the culture media in a concentration of 300µM.  
For passaging and further use, the cells were kept in a laminar flow hood that helped to avoid 
contamination. All reagents were heated to 37°C in a water bath prior to use. First, cells were rinsed 
with PBS to remove all traces of culture media, especially serum. Then, a small amount of Trypsin-
EDTA that just about covered the surface of the culture dish was applied and cells were incubated 
for up to 10 minutes, until they began to detach from the plastic. Subsequently, culture media was 
added to the Trypsin-EDTA in a 3:1-ratio, in order to deactivate the latter. After rinsing the surface 
of the culture dish a couple of times to ensure detaching of cells, the suspension was aspirated in a 
pipette and transferred to a 50ml-tube, which was then centrifuged at 200xG for three minutes. 
After decanting of the supernatant, the resulting cell pellet was re-suspended in culture media, in 
order to be redistributed among culture dishes at the desired ratio.  
For performance of luciferase assays, the Dual Luciferase Reporter Assay System was used, that 
allowed to measure both Firefly and Renilla luciferase. If Renilla luciferase was not co-transfected, 
the Luciferase Assay System was used. To begin, culture media was removed and the cells rinsed 
with PBS. Afterwards, a lysis buffer was applied and the lysate was either analyzed at once, or stored 
at -20°C. The assay was performed according to the manufacturer’s instructions, using the provided 
reagents and a luminometer for signal detection.  
2.2.1.2 Freezing and thawing of cells 
To freeze cells that were currently not used for experiments, a part of the cell suspension after 
centrifugation was not re-distributed, but instead added to a freezing tube the size of 2ml in a 1:1-
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ratio with a previously composed freezing medium. The latter contained culture medium and DMSO 
in a 4:1-ratio. The tubes were stacked in a box containing isopropanol before storage at -80°C, to 
prevent the cells suffering damage from rapid freezing. After cooling down overnight at -80°C, the 
tubes were transferred to a liquid nitrogen tank. From there, the tubes were removed if cells were 
needed and could be rapidly thawed in the water bath. After adding the thawed cell suspension to 
fresh media in a culture dish, the cells could be placed in the incubator overnight and received fresh 
media the next day to remove all traces of DMSO.  
2.2.1.3 Counting cells 
For certain in vitro experiments, the cells needed to be counted. To this effect, the cells were 
suspended in a particular volume and a small amount of the suspension was mixed with Trypan blue 
solution (0.4%), a marker for dead cells, at a 1:1-ratio. The resulting mix could be applied to a 
Neubauer counting chamber, which is only able to hold a certain volume. It was then possible to 
deduct the number of cells per ml in the original suspension from the mean number of viable cells 
counted in each of the four fields within the chamber, by multiplying the latter by 104.  
2.2.1.4 Creation and handling of spheroids 
For the creation of spheroids, a multitude of different approaches has been developed in the past. 
For this study, the spheroids needed to be as precisely rotund as possible, as oxygen gradients 
within the spheroid played a key role. To achieve this, it was agreed to try and grow spheroids from 
single cells, rather than pressing cells into a composite by for example centrifugation.  
Polyhydroxyethylmethacrylate, referred to from here on in as polyHEMA, is a hydrophilic polymer 
that can be used to reduce the adherence of cells to the surface of a culture dish to a minimum. 
Dissolved in 96%-ethanol to a concentration of 120mg/ml and mixed overnight on a magnetic 
twirler, it formed a liquid that could be stored at 4°C. To be used for the coating of culture dishes, it 
was further diluted in 96%-ethanol in a 1:10-ratio. For a 10cm culture dish, 3-4ml of this dilution was 
added to the surface and the dish subsequently placed under the laminar flow hood for it to dry 
with the help of a drain of air and without fear of contamination. After a couple of hours, the 
polyHEMA-coat had dried and provided a clean surface for cells to be placed upon but not attach to. 
The polyHEMA-coated culture dish was filled with culture media and a very small number of cells 
were added to the media. The dish was then placed in an incubator for several days and over the 
course of time, with the cells not having a surface to attach to, they started growing in spheroids. 
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Depending on the cell line, different sizes of spheroids could be seen after a certain time. For Huh7 
cells, typically after 6-10 days, the spheroids had grown to the desired size between 400 and 600 
µm. Every couple of days, to supply the spheroids with fresh media, it was partly exchanged. By 
rotating the dish on a flat surface, spheroids assembled in the middle of the dish and the media 
could be aspirated at the periphery without accidentally gathering up spheroids. The same 
technique was applied to purposely extract spheroids from the dish.  
2.2.1.5 Spheroid invasion assay 
In order to investigate whether MSC could invade a tumor spheroid under these in vitro conditions, 
the first invasion assays were conducted with a simple experimental design. Primary MSC, obtained 
from a bone marrow aspirate, were stained with 10µM CMFDA, a green fluorescent marker, and 
added to the culture media in a dish that already contained tumor spheroids that had been growing 
for a week and had reached the desired size of 400 to 600 µm. After 72 hours of incubation, the 
spheroids were extracted from the dish, prepared for and cryo-sectioned as detailed above. For 
fluorescent microscopy, the slides were stained with DAPI, a blue fluorescent marker of cell 
nucleuses, and mounted with 50%-glycerin-0.2%NPG-PBS.  
To get an idea of the distribution of oxygen within the spheroids, a pimonidazole staining was added 
to the method. Pimonidazole is a 2-nitroimidazole that is reductively activated in hypoxic cells and 
subsequently forms stable complexes with thiol-groups in other molecules that can be detected by 
immunohistochemistry (Franko 1986). Pimonidazole reagent and antibody were used according to 
the manufacturer’s instructions (Hypoxyprobe).  
After demonstrating that the primary MSC invaded the Huh7 tumor spheroids, the experimental 
design was further refined. One goals was to control the number of MSC that were added, and to 
isolate the spheroids for the purpose of the assay, so that every spheroid plus the MSC added to the 
culture media of the respective spheroid became an experimental unit. To achieve this, the MSC 
were stained with CMFDA (10µM), harvested and counted. 25 000 CMFDA-labelled MSC were re-
suspended in 25µl culture media and added to a 1.5ml-tube, that already contained a tumor 
spheroid, also gathered up in 25µl culture media. The tubes were then placed on a roller plate for 2 
hours. During that time, all the tubes were stacked together in a 50ml-tube and assembled in a way 
that made sure, none of them were positioned upside down during the process of rolling, with the 
danger of the spheroid attaching to any surface. After rolling, the tubes were carefully dislodged and 
the spheroids were gathered up in a pipette tip and transferred to the well of a 96-well-plate, each 
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spheroid again on their own. Subsequently, the culture media was exchanged three times, so as to 
wash away all remaining MSC that had been unable to attach to the spheroid. In the end, spheroids 
were cultured in 100µl media for the duration of 48 hours at 37°C. Afterwards, the spheroids were 
extracted from the wells, prepared for and cryo-sectioned as detailed above. For fluorescent 
microscopy, the slides were processed as detailed in chapter 2.2.5.3. 
2.2.2 Molecular Biology 
2.2.2.1 Freezing and thawing of bacteria 
All plasmid constructs were transformed into E.coli strains (DH5α or for Multisite Gateway cloning, 
Mach1). Long-term storage was achieved by adding 100µl of a previously composed freezing 
medium to 900µl of an overnight culture and storing the mix at -80°C. In order to restart culture 
from that vial in stock, a small amount of frozen bacteria was scratched away from the surface and 
dispersed on an agar plate with a thinning streak. The plate was then cultured at 37°C overnight and 
a single colony was picked the next day, of which a liquid culture could be started.  
2.2.2.2 Preparation of agar plates 
Agar plates were prepared regularly with the desired selective antibiotic. Here, a 3% Agar solution 
was heated in a microwave and mixed with an equal volume of 2x LB medium. For DH5α bacteria, 
100µg/ml Ampicillin was added, Mach1 bacteria required a higher concentration of 150µg/ml. The 
mixture was poured into petri dishes, which were then set out to cool down and dry under a laminar 
flow hood. For storage purposes, the plates were all packed and sealed in plastic bag and kept at 
4°C. 
2.2.2.3 DNA restriction digests 
For restriction digests of DNA, either to cut out fragments or to verify correct internalization of 
fragments into destination vectors, the following experimental set-up was applied: 1µg of DNA was 
digested with 1 unit of restriction enzyme in the span of 1 hour. For larger DNA amounts, either 
more of the restriction enzyme was used or the reaction time was extended. In case of the former, 
reaction volume was increased accordingly, so that the enzyme volume never surpassed one tenth 
of the total volume. Another tenth of the reaction volume was taken up by the respective restriction 
buffer that had been supplied by the manufacturer. All reactions, if not indicated otherwise by the 
manufacturer, took place at 37°C in a table top shaking device at 300rpm.  
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2.2.2.4 Separation of DNA fragments by electrophoresis 
Agarose gel electrophoresis was applied either for diagnostic tests on DNA fragments in terms of 
size or correct restriction digests, or in order to isolate and prepare said DNA fragments, for example 
after amplification by PCR. Agarose concentration varied between 0.6% and 2%, depending on the 
expected size of the fragment in question. Typically, for a fragment larger than 1000 base pairs a 
concentration of 0.6% would suffice, whereas a fragment smaller than 1000 base pairs required a 
2% agarose gel. The gel consisted of 0.5xTBE buffer, containing ethidium bromide in a concentration 
of 100ng/ml, mixed with the desired amount of agarose powder, which was subsequently dissolved 
by heating the mix in a microwave until it turned transparent. The heated agarose gel was dispersed 
in an appropriate electrophoresis chamber. Before applying them to their allocated slots, DNA 
samples were mixed with blue 6x loading buffer in a 5:1-ratio. Next, the chamber was topped with 
the aforementioned 0.5x TBE buffer and a voltage of 120 was applied. The gels were observed and 
documented under a UV lamp and, if necessary, fragments were cut out and subsequently extracted 
from the gel using a commercial kit (QIAquick Gel Extraction Kit). 
2.2.2.5 Determination of DNA concentrations 
In order to determine DNA concentrations, the Qubit fluorometer was utilized, along with 
commercially available reagents (Quant-iT) supplied by the same manufacturer. All assays have been 
performed according to the instructions of the manufacturer.  
2.2.2.6 Dephosphorylation and ligation of DNA ends 
In order to avoid religation of single-cut DNA ends in ligation reactions, an additional step in 
between restriction digest and ligation was necessary. This step involved the dephosphorylation of 
two ends of a fragment that had been cut out or linearized by digest with a single cutting restriction 
enzyme. Without the phosphate, the DNA molecule was not able to re-ligate with itself. To this 
effect, one of the two DNA molecules that were supposed to be ligated in the following reaction, 
typically the plasmid, was incubated for another hour at 37°C with a commercially available calf 
intestine alkaline phosphatase (CIP) that catalyzes the dephosphorylation of both the 5’ and the 3’ 
end. Subsequently, the DNA molecule had to be purified again, using a commercially available kit 
(QIAquick PCR Purification Kit).  
For the ligation of vector and insert DNA fragments, both were included in a reaction containing a 
ligation enzyme, in this case a commercially available T4 DNA ligase. According to laboratory 
protocol, four different reactions were prepared. Two of these reactions contained both fragments, 
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vector and insert, in a 1:3- and 1:10-ratio of molar weight, respectively. A third reaction contained 
the uncut plasmid and served as positive control, while a potential fourth reaction contained the cut 
and “CIP-ed” plasmid and served as a negative control. 1µl T4 DNA ligase was added to the mix in a 
concentration of 400 U/µl, along with 2µl of a 10x ligase buffer (supplied by the manufacturer) and 
the reaction volume was topped up to 20µl with water. After 1 hour incubation at room 
temperature, typically one tenth of the total reaction volume was transformed into competent 
bacteria.  
2.2.2.7 Preparation and transformation of competent E.coli DH5α and Mach1 
Competent DH5α bacteria were prepared according to a standard laboratory protocol with the help 
of a calcium chloride (CaCl2) solution. To this effect, a 4ml overnight liquid culture of E.coli DH5α was 
added to 400ml fresh LB medium and incubated at 37°C and 250rpm. During that time, the optical 
density was reassessed every couple of minutes by absorption spectroscopy of a culture sample. 
Once an OD600nm of 0.375 was reached, the bacterial culture was aliquoted in 50ml tubes, kept on ice 
for 5 minutes and centrifuged at 4°C and 1600xG for 7 minutes. Afterwards, the supernatant was 
discarded and the bacteria in each aliquot re-suspended in 10ml of an ice-cold CaCl2 solution. 30 
minutes incubation on ice were followed by another centrifugation step identical to the previous 
one. Now, the bacteria in each aliquot were re-suspended in 2ml of an ice-cold CaCl2 solution and 
re-dispersed in smaller aliquots of 200µl. These aliquots were then snap-frozen by immersing them 
in a bath of ethanol and dry ice, before storing them at -80°C. Competent E.coli Mach1 bacteria 
were obtained from Invitrogen. 
For transformation of both E.coli DH5α and Mach1 bacteria, one tenth of the ligation reaction 
volume was added to a tube containing 50µl of rapidly thawed bacteria and kept on ice for 10 
minutes. Subsequently, the tubes were stacked into a table-top heater and exposed to 42°C heat for 
exactly 45 seconds. Afterwards, the bacteria were re-suspended in pre-warmed LB medium and 
incubated for another 45 minutes at 37°C and 300rpm. This suspension was then plated on agar 
plates containing the desired selective antibiotic and incubated overnight at 37°C. The next morning, 
single colonies could be picked from the plate and seeded into a liquid culture. 
2.2.2.8 Isolation and analysis of plasmid DNA from transformed bacteria 
In order to analyze plasmid DNA from transformed bacteria, the latter had to be lysed and the DNA 
isolated from the lysate. For this step, a commercially available kit was used, depending on the size 
of the overnight culture (Innuprep Plasmid Mini Kit for cultures up to 1.5ml, Endofree Plasmid Maxi 
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Kit for culture up to 100ml) and according to the manufacturer’s instructions. For analysis, 
diagnostic restriction digests were performed and evaluated by gel electrophoresis.  
2.2.2.9 Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) was used in this study to amplify the desired inserts for the 
Multisite Gateway cloning and at the same time add the relevant attB-recombination sites. To this 
effect, primers that contained both the necessary short nucleotide sequences for recombination as 
well as the complement nucleotides that were able to attach to the DNA that was to be amplified, 
were designed using the Clone Manager software. For all reaction mixtures, the same protocol was 
adhered to (see table 1). PCR settings can be observed in table 2. For primer sequences please turn 
to chapter 2.1.8. The inserts were amplified and purified by gel electrophoresis and extraction. 
 volume (µl) 
dNTP 4 
fw-primer 1 
rv-primer 1 
Phusion 
Polymerase 
1 
HF-buffer 5 
Target DNA 
(5-10ng/µl) 
1 
H2O 12 
Table 1: Standard reaction mixture for PCR. DNA was diluted to a concentration between 5 and 10 ng/µl before use, one 
reaction mix always adding up to a volume of 25µl in total. To amplify the insert sufficiently, 5 PCR reactions were 
performed at the same time. Afterwards, they were pooled together and dispensed across the slots of an agarose gel. 
 6xHRE-tk 
(412bp) 
HSP70b 
(590bp) 
mCherry 
(821bp) 
Gaussia 
(633bp) 
TK-pA 
(1801bp) 
Template PGL3-hypoxia-
luc (6401bp) 
PGL3-HSP70b 
(5268bp) 
pCAG-Cherry  
(7100bp) 
pN3-BAR-Gluc 
(4200bp) 
PGL3-RaPro-
TK 
(6800bp) 
Initial 
denaturation 
95°C 
5 min 
95°C 
5 min 
95°C 
5 min 
95°C 
5 min 
95°C 
5 min 
Denaturation 95°C 
30 sec 
95°C 
30 sec 
95°C 
30 sec 
95°C 
30 sec 
95°C 
30 sec 
Annealing 61°C 
30 sec 
61°C 
30 sec 
58°C 
30 sec 
64°C 
30 sec 
63°C 
30 sec 
Elongation 72°C 
3 min 
72°C 
2.5 min 
72°C 
3.5 min 
72°C 
2 min 
72°C 
3.5 min 
Cycles 30x 30x 30x 30x 30x 
Final 
elongation 
72°C 
10 min 
72°C 
10 min 
72°C 
10 min 
72°C 
10 min 
72°C 
10 min 
Table 2: PCR settings. Elongation time was chosen depending on template size (30 sec per 1000bp). 
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2.2.2.10 Sequencing of DNA 
Sequencing of DNA was performed by GATC Biotech, Konstanz. Primers used in the process of 
sequencing that are not standard primers are listed in chapter 2.1.8.  
2.2.2.11 Transient Transfections in L87 and primary MSC 
Transient transfection of L87 cells were either conducted by lipofectamine or electroporation. For 
both methods, the plasmids were isolated and suspended in sterile H2O. In most experiments, an 
additional plasmid carrying a Renilla luciferase driven by a CMV-promoter was added in a 1:50-ratio. 
In the case of lipofectamine, a commercially available kit (Lipofectamine) was used and 
concentrations as well as cell numbers and incubation times were applied according to the 
manufacturer’s instructions. After transfection, culture medium was exchanged after 4 to 6 hours 
and cells were left in the incubator over night before starting stimulation. For primary MSC, 
lipofectamine was the only transfection method applied in the course of this study. 
For electroporation, L87 cells were seeded out to reach an 80% density overnight, to ensure they 
had entered a logarithmic growth phase on the day of transfection. The plasmid DNA was re-
suspended in sterile, endonuclease-free water to a concentration of 1-3µg/µl. The cells were 
counted and re-suspended in culture medium containing 10% FCS but no antibiotics to a 
concentration of one million cells per 100µl. A disposable electroporation cuvette with a 4mm gap 
was filled with 200µl of cell suspension and 4µg plasmid DNA (plus a potential 0.08µg pRL-CMV) was 
added to the mix. The cuvette was kept on ice for 10 minutes before electroporation, which was 
performed at 960µF and 230V. Afterwards, the cuvette was kept on ice for another 10 minutes. To 
transfer the cells from the cuvette to the culture dish, the cuvette was flushed with 200µl culture 
medium. If a higher number of transfected cells than 2 million were required, electroporation was 
performed in several identical steps and the cell suspension was pooled again after transfection, to 
be distributed across multiple wells.  
2.2.2.12 Stable Transfection of L87 
Stable transfection of L87 with the pcDNA-ITR-HIF-Cherry construct in this study has been achieved 
using a sleeping beauty-based transposon system. The vector backbone carried two indirect 
terminal repeats (ITR), flanking the promoter and transgene as well as the selective marker, in this 
case a blasticidin resistance. The sleeping beauty transposon system requires a transposase 
(SB100X) to be co-transfected with the plasmid. The ratio between pcDNA-ITR-HIF-Cherry and the 
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plasmid carrying the SB100X-transposase was 1:3. After transfection, the transposase facilitated 
excision of the transposon from the plasmid and inserted it into the genome of the cell at TA 
dinucleotides.  
In the course of this study, L87 cells were transfected with pcDNA-ITR-HIF-Cherry (20µg) and SB100X 
(60µg) by using electroporation. Experimental parameters were the same as detailed above 
regarding transient transfection, except for DNA concentrations. A total of 3 million cells were 
transfected and transferred into a 10cm culture dish afterwards. 48 hours after transfection, the 
culture medium was removed and replaced by fresh medium containing 6µg/ml blasticidin. During 
the next 14 days, selective medium was exchanged every 72 hours.  
2.2.3 Cloning strategies 
2.2.3.1 Construction of pGL3-hypoxia-luc 
For in vitro studies of hypoxia in MSC, a plasmid was obtained from Prof. Grässer of Saarland 
University, Bad Homburg, that carried the hypoxia-sensitive 6xHRE-tk-promoter inserted in the 
multiple cloning site. The foundation of this vector is the commercially available pGL3-Basic vector 
(Promega). To be able to use this plasmid in a potential stable transfection experiment, a selective 
marker for human cell culture had to be integrated into the backbone. To this effect, pCMV-Bsd (Life 
Technologies), also a commercially available plasmid, was examined for mutual restriction sites. In 
the end, the blasticidin resistance gene that is driven by a human CMV-promoter was excised from 
the vector by restriction digest with BamHI and BglII. At the same time, the aforementioned pGL3-
Basic vector carrying the 6xHRE-tk-promoter, was linearized by restriction digest with BamHI alone 
and incubated with an alkaline phosphatase to dephosphorylate both ends. Subsequently, the CMV-
blasticidin insert was ligated into the BamHI-site, with the possibility of a clockwise or 
counterclockwise integration. The new vector would lose one of the BamHI ends to ligation with 
BglII and contain once again a single cutter BamHI site on the other end of the insert. To verify 
correct integration and orientation, the resulting clones were digested with XbaI and EcoRI. XbaI 
represented a single cutter in the original pGL3-Basic vector, while EcoRI only cutting in case of 
correct integration of the insert. The length of the fragment excised out of the newly-constructed 
pGL3-hypoxia-luc in the course of this control digest depended on insert orientation and either 
came up as short as 300 base pairs (counterclockwise) or 1600 base pairs (clockwise). For the 
following in vitro studies, the clockwise orientation was preferred. 
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2.2.3.2 Construction of pcDNA-ITR-HIF-Cherry and pcDNA-ITR-HSP70b-Cherry 
Originally, MSC were transfected with a construct similar to pGL3-hypoxia-luc that had the firefly 
luciferase replaced by a red fluorescent protein. However, after various efforts to stably integrate 
the transgene into MSC, a new strategy was devised. As the efficiency of plasmid integration into 
the MSC genome was identified as a key problem, a system was devised that assured higher 
transfection efficiency. To achieve that the promoter and the reporter gene were integrated into a 
vector containing two inverted terminal repeats (ITR), which are needed for transfection with the 
Sleeping Beauty transposon system. These nucleotide sequences are crucial for transposition, as 
they are identified by the transposase and lead to excision of the transposon.  
For the new construct, the commercially available Multisite Gateway Pro Plus kit was applied. With 
the help of this recombinational cloning tool, several new vectors could be produced in a short time 
span. This method is referred to several times throughout this study and is outlined in the following. 
The Gateway cloning system is based upon site-specific recombination between the lambda 
bacteriophage and E.coli bacteria. In short, bacteriophageal enzymes, the recombinases, are able to 
attach to certain nucleotide sequences, the attachment or att sites, in both strands and 
recombination takes place as the flanking regions of matching att sites are interchanged. There is no 
nucleotide gain or loss in the process, instead new att sites are created that are hybrids with 
nucleotides from both donor strands. The Gateway cloning system makes use of proteins from both 
bacteriophage and E.coli that catalyze the recombination reactions (BP and LR reaction) and uses 
the same 15 base pair core regions within the original att sites. These core regions are flanked by 
additional nucleotides that help the recombinases attach to the DNA.  
Recombinational cloning speeds up the process, because it merges several conventional cloning 
steps into one. It allows cloning all modules, promoters as well as expression genes, into the 
destination vector at the same time. Correct integration in the right order is guaranteed by 
equipping PCR products with the respective att sites. Figure 1 is a schematic outline of the different 
stages of recombinational cloning with the Gateway system. AttB sites have to be integrated into 
PCR primers before amplification of the insert, whereas pDONR-vectors are supplied by the 
manufacturer and already contain the matching attP sites. PCR primers were designed using the 
Clone Manager software. Table 3 shows primer sequences and highlights template-specific 
nucleotides and att sites. The amplicons containing the promoters were flanked by an attB1 site on 
the 5’ end and an attB5r site on the 3’ end. The reporter genes were flanked by attB5 and attB2, 
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respectively. In the following BP reaction that represents the lysogenic pathway of recombination 
between bacteriophage and E.coli, the promoters were integrated into pDONR-221-P2P5r, whereas 
the reporter genes were integrated into pDONR-221-P5P2. The donor vectors as well as the 
destination vector carry a ccdB-gene between att sites. The ccdB-gene is a bacterial toxin originating 
from the E.coli genome that leads to death of transformed bacteria, if it is not replaced by the gene 
of interest during recombination, and therefore serves as a control for correct process of 
recombination. For plasmid maps of the entry clones please turn to chapters 3.2.3.1 and 3.3.3 
(Jaeckel 2016). 
With both promoters, 6xHRE-tk and HSP70b, as well as expression genes, Gaussia luciferase, 
mCherry fluorescent protein and thymidine kinase, integrated into entry clones, six new plasmids 
could be generated at the same time in a system of mix and match. The destination vector in this 
study, pcDNA6.2PLITRBlasti-Dest, was kindly provided by Carsten Jäckel. It contains the necessary 
attR1 and attR2 sites with the ccdB-gene in between as well as the desired ITR sites for sleeping 
beauty transposition and a blasticidin resistance gene. In the following LR reactions that represent 
the lytic pathway of recombination between bacteriophage and E.coli, the six new plasmids evolved, 
namely pcDNA-ITR-HIF-Cherry (see chapter 3.2.3.1) and pcDNA-ITR-HSP70b-Cherry (see chapter 
3.3.3) (Jaeckel 2016). 
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Figure 1: Schematic outline of the Gateway technology. AttB sites always recombinate with attP sites in a BP reaction, 
while attL sites always recombinate with attR sites in an LR reaction. Source: MultiSite Gateway Pro® User Guide. 
Att-
sites 
Insert Fw/
Rv 
Sequence 
B1 
B5r 
6xHRE-tk/ 
HSP70b 
Fw GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATAGGTACCGAGCTCTTACG 
Rv GGGGACAACTTTTGTATACAAAGTTGTTACCAACAGTACCGGAATGC 
B5-
B2 
mCherry Fw GGGGACAACTTTGTATACAAAAGTTGTAGCAGCCACCATGTCTAG 
Rv GGGGACCACTTTGTACAAGAAAGCTGGGTTGCCTTCACAAAGATCCTCTA 
Gaussia-
luciferase 
Fw GGGGACAACTTTGTATACAAAAGTTGTAATCCAGCCACCATGGGAGTC 
Rv GGGGACCACTTTGTACAAGAAAGCTGGGTTGGCCGCTTAGTCACCACC 
Thymidine 
kinase 
Fw GGGGACAACTTTGTATACAAAAGTTGTACAGCCTCTCCCACAGGTAC 
Rv GGGGACCACTTTGTACAAGAAAGCTGGGTTTAAAACGACGGCCAGTGC 
Table 3: Primer sequences. Att sites are highlighted in yellow, template-specific sequences in blue. Primers for 6xHRE-tk 
and HSP70b promoters have the same template-specific sequence, as they are both integrated into pGL3-basic. 
2.2.4 Protein-based methods 
2.2.4.1 Western blot 
In order to measure HIF1α protein expression in MSC by western blot, proteins had to be extracted 
from the cells. Unfortunately, as mentioned before in the introduction, HIF1α is dismantled rather 
quickly once cells find themselves in a normoxic environment. To avoid this, a special extraction 
buffer had to be composed, that was based on several publications on the topic as well as previous 
protocols from other laboratory members. For all buffers mentioned in this section, compilations 
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are listed in chapter 2.1.3.1. In short, the buffer applied in this study served to extract a whole cell 
lysate and contained cobalt chloride to a concentration of 1 mM. Cells were washed in 4°C PBS and 
subsequently scraped off the culture dish with RIPA buffer, transferred to a reaction tube and kept 
on ice for one hour. Centrifugation at 13000rpm and 4°C for 20 minutes followed and the 
supernatant was aliquoted and stored at -20°C.  
A polyacrylamide gel was prepared with an acrylamide concentration gradient increasing from 5% to 
8%, with an additional 6% step in between. This way, both HIF1α at 140 kDa and α-tubulin at 52 kDA 
could be accommodated and separated at the optimal gel concentration. SDS-PAGE was performed 
according to Laemmli (Laemmli 1970). Extracts were mixed with Laemmli reducing buffer and 
heated at 95°C for five minutes before loading them on the gel along with a MagicMark size 
standard for molecular weight control. Electrophoresis was started at 80V and continued at 120V 
once all samples had visibly entered the gel.  
Western Blot was performed according to Towbin (Towbin 1979). At the end of electrophoresis, the 
gels were blotted onto polyvinylidene fluoride (PVDF) membranes and the proteins transferred in 
NuPage buffer at 30V for one hour (wet blot technique). The membranes were then blocked with a 
blocking solution (5% skim milk powder in TBST) for either 1 hour at room temperature or overnight 
at 4°C and washed twice in water before application of the primary antibody. The primary antibody, 
a mouse anti-human HIF1α, was diluted in a 1:1000-ratio in TBST and applied either for 2 hours at 
room temperature or again at 4°C overnight. Four washings with TBST at 10 minutes each followed, 
before adding the secondary antibody, in this case rabbit anti-mouse IgG, diluted 1:5000 in TBST 
with 5% skim milk powder. To avoid high background, incubation with the secondary antibody was 
limited to 1 hour. To conclude, four washings with TBST at 10 minutes each and two additional 
rounds of TBS for 5 minutes ensued. The membrane was then soaked in 4ml ECL solution for 1 
minute, exposed to radiography and the resulting film processed in a developing machine.  
2.2.4.2 ELISA 
ELISA was applied for quantification of CCL5 in cell culture supernatants. The supernatants were 
collected and stored at -20°C and subjected to ELISA at various dilutions. For the assay, a 
commercially available sandwich ELISA (DuoSet) for CCL5 was used, according to the manufacturer’s 
instructions. Chromogenic development was achieved by adding OptEIA substrate solution. 
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2.2.5 In vitro experiments 
2.2.5.1 Fluorescence activated cell scanning (FACS) 
FACS analysis and sorting of stably transfected L87-HIF-Cherry was done in collaboration with Dr. 
Josef Mysliwietz and Prof. Dr. Elfriede Nößner of the Helmholtz Zentrum Munich, Institut für 
Molekulare Immunologie. The FACS machine, a BD FACSAria III, is equipped with a 561nm-laser that 
is able to excite (587nm) and detect (610nm) the mCherry red fluorochrome at near-optimal 
wavelengths. Analysis and sorting both relied on ordinary L87 cells as negative control in order to 
establish sorting gates. After detection, mCherry-positive cells were released directly into a 1.5ml 
reaction tube that was filled with culture medium and 30% FCS.  
2.2.5.2 Fluorescence microscopy of cells 
To verify expression of the mCherry red fluorochrome in transfected L87-HIF-Cherry, cells were 
analyzed with an inverted microscope and the necessary fluorescence filters.  
2.2.5.3 Immunofluorescent staining and microscopy of spheroids 
Spheroids were analyzed following cryosection and fluorescence microscopy. For analysis, the 
spheroids needed were embedded in OCT compound, a transparent gel at room temperature, and 
cut with a cryotome. To this effect, the spheroids were gathered from the dish and transferred into 
a 1.5ml tube. Spheroids quickly descended to the bottom of the tube, so that the excessive culture 
media could easily be removed with a pipette. The spheroids were pipetted on to the OCT 
compound along with a miniscule remnant of media, which could be removed fully once the 
spheroids had begun to subside into the gel. The goal was to transfer the spheroids into a cassette 
filled with OCT compound with as little media as possible, to limit the amount of H2O, which tends 
to ruin the chances of attaining a clean slice with the cryotome later on. The cassettes were then 
frozen and stored at -20°C for further processing. 16 to 18µm thin slices were obtained at the 
cryotome and gathered up on slides immediately. The slides were left outside the cryotome at room 
temperature to air-dry for a couple of minutes, before immersing them in a container with 4°C cold 
formalin for fixation. If the spheroids had been exposed to pimonidazole before, pimonidazole 
antibody was applied according to the manufacturer’s instructions (0.6µg/ml). As a second antibody 
and in order to allow for the pimonidazole stain to be analyzed by fluorescence microscopy, red 
fluorescent AlexaFluor594-labelled anti-donkey-IgG was used (3.75µg/ml). For fluorescent 
microscopy, the slides were stained with DAPI, a blue fluorescent marker of cell nucleuses, and 
mounted with 50%-glycerin-0.2%NPG-PBS. 
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3 Results 
The aim of this study was to better characterize CCL5-based engineered MSC, and to evaluate new 
targeting strategies. Herein, the study focused on tumor hypoxia and externally applied 
hyperthermia. To this end, three different targeting strategies were examined for genetically 
engineered MSC: using gene promoters based on CCL5, HIF1α HSP70b biology. 
3.1 Rantes/CCL5 is activated in MSCs in tumor stroma via inflammatory cytokines 
3.1.1 IL1-β, TNF-α and γIFN appear to be responsible for CCL5 activation in tumor stroma 
As was previously shown in the work of Christoph Zischek and colleagues, CCL5 biology can be used 
to enhance the specificity of genetically engineered MSC. CCL5 is up-regulated in MSC that have 
infiltrated tumor stroma. When adoptively applied MSC invade growing tumor stroma, a CCL5-
driven reporter or therapeutic gene can become activated specifically in the desired area.  
What was largely unknown, was which factors present in the tumor stroma lead to the up-regulation 
of CCL5 seen in MSC. As we know from previous studies, CCL5 serves as a stress response signal. As 
a first step, immortalized MSC (Alex-2) were used for in vitro experiments to measure CCL5 protein 
production in the supernatant via specific ELISA, in response to treatment with a range of cytokines 
associated with tumor inflammation and the stress response, namely IL-6, VEGF, TNF-α, IL-10, 
Wnt5a, IL-1β, γ-IFN and TGF-β1. These cytokines are thought to be present in the tumor 
microenvironment and thus may influence the ability of cells to respond to inflammatory signals. As 
detailed in chapter 1.1, both IL-6 and TGF-β1 are involved in recruitment, activation and 
differentiation of tumor-associated fibroblasts within the tumor microenvironment. Wnt5a is 
thought to have both tumor-suppressive and tumor-promoting effects, for instance through 
enhanced differentiation of tumor-associated fibroblasts (Endo 2014). VEGF is responsible for 
increasing oxygen supply to the tumor stroma by inducing angiogenesis (see chapter 1.2) and 
Voronov et al were able to show similar effects of IL-1β (Voronov 2003). TNF-α has been previously 
shown to be a potent activator of CCL5 expression in some, but not all cell types (see chapter 1.2.1). 
IL-10 is thought to reduce inflammation and could thus potentially limit CCL5 expression (Sabat 
2010). Last but not least, γ-IFN has been shown to recruit immune-modulating cells to the scene of 
inflammation, as was detailed in chapter 1.1.  
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The results provided in Figure 2-B show a ten-fold increase in CCL5 expression after 24h incubation 
with TNF-α at various concentrations.  A five-fold activation was provoked by stimulation with IL-1β. 
Only a moderate effect was seen with stimulation by γIFN. A combined and more powerful effect 
was seen through double stimulation, for example with TNF-α and γ-IFN. While the effect of γ-IFN 
alone on CCL5 expression was not significant, the combination of TNF-α and γ-IFN created a more 
than additive effect than that seen with TNF-α alone. TGF-β1 has been proposed to activate CCL5 
expression in tumor fibroblasts (Borczuk 2008). However, the experiments here showed that 
treatment with TGF-β1 was not able to induce expression of CCL5 by MSC. In subsequent ELISA 
experiments, the potential interplay of TNF-α, IL1-β and γ-IFN was examined in more detail. Figure 2 
shows again that stimulation through γIFN does not produce a significant effect. However, a 
combination of TNF-α and γIFN was able to enhance CCL5 expression more than with TNF-α alone. 
The biggest effect was achieved by stimulating CCL5 expression with all three cytokines at once. This 
suggests that the activation of CCL5 in MSC that have invaded tumor stroma is to a great extent 
regulated by an inflammatory milieu.  
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Figure 2: In vitro stimulation of CCL5 expression (ELISA). (A-H) Cells (Alex-2) were seeded in 96-well plates and cytokines 
added six hours later. After 36h incubation, the supernatant was harvested and immediately stored at -20°C. ELISA was 
performed with a 1:100 dilution of the supernatant. Recombinant human cytokines (commercially available) were used. 
Concentrations in single cytokine assays (n=1) as indicated within the graphs for the respective cytokine, concentrations 
for additional cytokines (n=2) as follows: IL1-β=1ng/ml, γIFN=10ng/ml, IL-6=1ng/ml, IL-10=1ng/ml, TGF-β1=0.1ng/ml, 
VEGF=1ng/ml, Wnt5a=10ng/ml. (I) Cells (Alex-2) were seeded out the previous day. Human recombinant cytokines were 
added along with reducing fetal calf serum (FCS) content to 5% instead of 10%. After 24h incubation, the supernatant was 
harvested and immediately stored at -20°C. Concentrations in single cytokine assays as indicated, concentrations for 
double or triple cytokine assays as follows: IL1β=1ng/ml, TNF-α=5ng/ml, γIFN=10ng/ml. Statistical analysis was performed 
by applying Mann-Whitney-U-Test (n=5, P=0.0079). Stimulation with γIFN alone yielded no significant result. 
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Measuring protein secretion was a good means of screening for factors that could induce native 
CCL5 production in MSC. To then determine if these effects could translate to moderation of CCL5 
promoter activity, a -971-upstream region of the human CCL5 gene promoter was cloned into an 
expression vector, and the construct was transiently introduced into two human MSC-lines (using 
either lipofectamine for Alex-2 or electroporation for L87), and the ability of the cells to respond to 
specific signals was monitored using firefly luciferase assays. To control for transfection efficiency, 
the control plasmid pRL-CMV was co-transfected at a 1:50-ratio and the firefly luciferase values 
were normalized to renilla luciferase. After transfection and overnight incubation, the cells were 
incubated for an additional 24h with recombinant human TNF-α or TGF-β1 added to cell culture 
media. Afterwards, the cells were lysed and the lysate subjected to a dual light luciferase assay. As 
demonstrated in figure 3, the addition of TNF-α causes a low but statistically relevant effect on 
luciferase activity. TGF-β1, on the other hand, produced no such effect, confirming the ELISA assays. 
 
Figure 3: In vitro stimulation of CCL5 expression (luciferase assay). (A) Cells (Alex-2) were seeded out in 96-well plates 
(n=5) and transiently transfected with PGL3-RFL using lipofectamy according to protocol. Six hours after transfection 
culture media was changed along with adding human recombinant TNF-α at indicated concentrations. After 24h 
incubation under normoxic conditions cells were lysed and luciferase activity was determined according to protocol. 
Statistical analysis was performed by using the Mann-Whitney-U-Test (**: P=0.0079, *: P=0.0159). The experiment was 
repeated several times to the same effect. (B) Cells (L87) were harvested and transiently transfected with PGL3-RFL using 
electroporation (230V; 1 million cells in 100µl culture media without antibiotic along with 4µg pGL3-RFL and 0.08µg pRL-
CMV per electroporation cuvette) before being seeded out in 96-well plates (n=5) and incubated at normoxia. Addition of 
human recombinant TGF-β1 followed after overnight incubation. 24h later, cells were lysed and luciferase activity was 
determined according to protocol. Statistical analysis was performed by applying Mann-Whitney-U-Test and yielded no 
significant result. The experiment was repeated several times to the same effect.   
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3.1.2 CCL5 is not stimulated by heat shock 
To further investigate the potential effect of heat shock, or hyperthermia on CCL5 transcription, 
immortalized MSC (L87) were transiently transfected, using lipofectamine, with the very same 
plasmid construct that has already been used for the previous experiments. After 24 hours 
incubation, the cells were exposed to hyperthermia using a water bath, with the temperature 
adjusted to 42°C. Exposure time was set to 30 minutes, after which the cells were returned to the 
standard incubator (37°C) for another 24 hours of incubation. Subsequently, the cells were lysed and 
the lysate tested for luciferase activity. The result of the luciferase assay is demonstrated in Figure 4-
A. No significant effect of heat shock on CCL5 expression can be noted. The experiment was 
repeated several times, to the same effect. 
3.1.3 CCL5 is not stimulated by hypoxia 
The expression of CCL5 is generally thought to be a response to stress. Tissue hypoxia poses a threat 
to the cell and the promoter region for CCL5 contains potential transcription factor binding sites for 
the HIF-1 factor (Nelson 1993). To test if hypoxia also potentially contributes to CCL5 promoter 
activity, MSC (L87, Alex-2) were transiently transfected with the CCL5 and control expression 
constructs. They were then placed in a hypoxic incubator, set to an oxygen level of 2% via 
insufflation of a gaseous mixture (95% nitrogen, 5% carbon dioxide), for a further 24h incubation. As 
shown in figures 4-B and 4-C, no significant effect on reporter activity was seen in response to 
hypoxic conditions. Because hypoxia is known to be a key player in tumor growth and prognosis, we 
then sought to determine if the general response of MSC to hypoxia could potentially act as an 
additional strategy for the activation of transgenes in engineered MSC. 
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Figure 4: In vitro stimulation of CCL5 expression by heat shock or hypoxia (luciferase assays). (A) Cells (L87) were seeded 
out in 96-well plates on day 1. On day 2, transient transfection with PGL3-RFL was performed by using lipofectamy 
according to protocol. 6 hours after Transfection, culture media was exchanged and cells were incubated for 24 hours at 
37°C. On day 3, cells were subjected to heat shock for 30 minutes by using a 42°C water bath. Cells were subsequently 
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returned to the 37°C incubator and incubated for another 24 hours, before being analysed for luciferase activity. The 
experiment was repeated several times and yielded no statistically significant result. (B) Cells (L87) were harvested and 
transiently transfected using electroporation (230V; 1 million cells in 100µl culture media without antibiotic along with 4µg 
pGL3-RFL and 0.08µg pRL-CMV per electroporation cuvette) before being seeded out in 96-well plates. Cells were then 
incubated at 21% oxygen overnight before one of the plates was being moved to a hypoxic incubator set to an oxygen level 
of 2%. After another 24 hours incubation, cells were lysed and luciferase activity was determined according to protocol. 
The experiment was repeated several times and yielded no statistically significant result. (C) Cells (Alex-2) were seeded out 
in 96-well plates (n=5) and transiently transfected with PGL3-RFL using lipofectamy according to protocol. Six hours after 
transfection culture media was changed and one plate was moved to a hypoxic incubator set to an oxygen level of 2%. 
After another 24 hours incubation, cells were lysed and luciferase activity was determined according to protocol. The 
experiment was repeated several times and yielded no statistically significant result. 
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3.2 HIF1α is stabilized in MSC in hypoxic areas of solid tumors 
3.2.1 pGL3-hypoxia: Hypoxia-responsive synthetic promoter comprised of six HIF1α-responsive 
elements driving a minimal promoter 
As detailed earlier, HIF1α is constantly expressed, but rapidly turned over in normoxic cells. The 
protein becomes stabilized under hypoxic conditions, and then acts as a transcription factor. One 
goal of this study was to develop a system where hypoxia in MSC could be easily detected through a 
promoter-reporter construct. The reporter construct used here was based on the idea that HIF1α, as 
a transcription factor, binds to specific short sequences of nucleotides within the promoter region of 
a gene in order to up-regulate gene expression. These consensus sequences for HIF1α-responsive 
elements (HRE) consist of five core nucleotides: A or G followed by CGTG. The promoter used in this 
study (which has been kindly provided by Prof. Dr. Grässer of Saarland University, Bad Homburg, 
Germany) contains six of these short sequences driving a minimal promoter based on the thymidine 
kinase (TK) promoter, as shown in figure 5.  
 
Figure 5: HIF1α-responsive elements (HRE) lined up on the 5’-end of a TK minimal promoter. 
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Figure 6: Plasmid map of pGL3-hypoxia-luc. A construct based on the pGL3-Basic by ProMega®, with the 6xHRE-promoter 
inserted in the multiple cloning site and a Blasticidin resistance inserted into the backbone. The latter was achieved by 
introducing CMV-Bsd at the BamHI site in the pGL3-vector.  
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3.2.2 In vitro HIF1α-stabilization in MSC using cobalt chloride treatment or a hypoxic incubator 
For in vitro studies in cell culture, HIF1α can be stabilized and thus studied, either by creating 
hypoxic conditions, for example by using a hypoxic incubator or a chamber system, or by artificially 
stabilizing HIF1α through chemical treatment, in this case by adding cobalt chloride to the culture 
media. Preliminary experiments revealed an astonishing robustness of MSC towards hypoxia. The 
oxygen level for experimental hypoxia used in this study was usually 2%. Cobalt chloride has been 
described in the literature as a potent HIF1α-stabilizer. Preliminary experiments regarding cobalt 
chloride concentrations suggested that 300µM represents an optimal concentration for the MSC 
experiments (data not shown). Cobalt chloride and the hypoxic incubator were directly compared 
with regards to HIF-1 activity in MSC. As observed in figure 7, hypoxic incubation of immortalized 
MSC (Alex-2) led to an increase of HIF1α protein concentration as determined by western blot. The 
next step was to transiently transfect immortalized MSC with the pGL3-hypoxia-luc (along with pRL-
CMV as positive control) and to quantify luciferase activity in response to either hypoxia (hypoxic 
incubator) or cobalt chloride. Similar results were obtained for both stimuli (Figure 8). Stimulation 
resulted in a ten-fold increase of luciferase activity. For transient transfections, pGL3-hypoxia-luc 
served as a good system. However, stable transfection would provide a more robust platform for 
subsequent experiments. To this end, it became necessary to optimize transfection efficiency and 
generate stable cell lines. 
 
Figure 7: HIF1α-stabilization in MSC in vitro through hypoxia. Cells (Alex-2) were plated out in 6cm culture dishes at 75% 
density and incubated overnight at the indicated conditions. Afterwards, cells were rinsed in PBS and extracts for western 
blot analysis were obtained by adding a pre-conditioned RIPA-buffer (see chapter 2.1.3.1 for more information). The cell 
lysate was subsequently incubated on ice for one hour, centrifuged and the supernatant stored at -20°C for future analysis. 
Exposure time: 5’. 
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Figure 8: HIF1α-induced transcription in MSC in vitro through hypoxia or cobalt chloride. (A)+(B) Cells (L87) were 
transiently transfected using electroporation (230V, 1 million cells per 100µl culture media without antibiotics, 4µg pGL3-
hypoxia plus 0.08µg pRL-CMV per cuvette) and incubated for 48 hours at the indicated conditions. Subsequently, cells 
were lysed and luciferase activity was determined according to protocol. For statistical analysis Welch-corrected t-test was 
applied (P=0.0024). 
3.2.3 pcDNA-ITR-HIF-Cherry/Gaussia/TK: integrating Sleeping Beauty into the backbone of the 
reporter vector enhances the efficiency of stable transfection in MSC 
3.2.3.1 Gateway Cloning 
In order to maximize the stable transfection efficiency of plasmid vectors, it was decided to make 
use of a Sleeping Beauty Transposon system. To this end, a plasmid was designed that had two ITR 
(inverted terminal repeats) sites flanking the region containing the promoter and the gene of 
interest, thus forming a transposon. For stable transfection, the cells were co-transfected with a 
plasmid containing the transposon and a second expression plasmid carrying the Sleeping Beauty 
transposase (SB100X). The transposase SB100X excises the transposon from the original plasmid and 
integrates it into the DNA of the host cells at specific TA dinucleotide sites (Jaeckel 2016). 
The general cloning strategy was also based on the Multisite Gateway Pro Plus kit, a commercially 
available kit. As was already mentioned in chapter 2.2.3.2, the kit allows to clone plasmids in a short 
time by applying a mix and match strategy. For this project, two different types of entry vectors 
(pENTR) were designed that could be integrated back to back into a destination vector (pDEST), 
forming a new plasmid, called an expression vector. The entry vectors contained either a promoter, 
in this case the hypoxia-sensitive 6xHRE-tk-promoter, or a reporter gene, either mCherry or Gaussia-
luficerase. For future experiments, an entry vector that contained thymidine kinase, a therapeutic 
gene, was designed simultaneously. 
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To create the entry vectors, the promoters and genes of interest had to be “copied” out of their 
original vector and amplified via PCR. To this end, primers were designed that could be used to 
duplicate the desired amplicon from the template, and at the same time, add the specific 
nucleotides at either end of the amplicon, that were needed to generate the sequences for the 
entry vector and expression vector.  
Forward and reverse primers were designed using the Clone Manager software under consideration 
of size and temperature and avoiding dimers. The attB recombination sites were added according to 
the manufacturer’s instructions. The amplicon containing the promoter was thus flanked by an 
attB1 site on the 5’ end and an attB5r site on the 3’ end. The reporter genes were flanked by attB5 
and attB2, respectively. For primer sequences please turn to chapter 2.1.8. The PCR products were 
then integrated into the entry vectors by performing the BP reaction (Figure 9). The resulting DNA 
constructs were checked for correct integration of the PCR products by restriction digest and 
sequencing (done by GATC). 
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Figure 9: pENTR221-vectors. (A) Entry vector containing the hypoxia-responsive promoter 6xHRE-tk now flanked by attL1 
and attR5 recombination sites (highlighted in red). (B) Entry vector containing the reporter gene mCherry now flanked by 
attL5 and attL2 recombination sites (highlighted in blue). AttR5 and attL5 recombination sites will later merge and create a 
new attB5 site. 
In the following LR reaction, recombination took place between the two entry clones and a 
destination vector, in this case pcDNA6.2PLITRBlasti-Dest, a plasmid provided by Carsten Jäckel that 
contains two Sleeping Beauty transposition sites framing the Gateway cloning site and a Blasticidin 
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resistance gene in the backbone (for a plasmid map, turn to chapter 2.2.3.2). The resulting 
expression vector pcDNA-ITR-HIF-Cherry contains the hypoxia-responsive promoter 6xHRE-tk 
followed by the reporter gene mCherry, flanked by the transposition sites, and an additional 
Blasticidin resistance in the backbone (Figure 10). Again, the resulting clones were checked for 
correct gene integration by restriction digest and sequencing (done by GATC). 
 
Figure 10: pcDNA-ITR-HIF-Cherry plasmid map. Sleeping Beauty transposition sites are highlighted in pink, att 
recombination sites are highlighted in yellow.  
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3.2.3.2 Creating a stable MSC cell line using pcDNA-ITR-HIF-Cherry 
The plasmid pcDNA-ITR-HIF-Cherry was subsequently used for stably transfecting MSC lines. The L87 
MSC cell line was used, as it could be passaged over a long period of time without ceasing to 
proliferate, while still maintaining key stem cell characteristics. For stable transfection, the pcDNA-
ITR-HIF-Cherry was added to the electroporation mix along with pCMV-SB100X, the plasmid 
containing the Sleeping Beauty transposase, in a 1:3-ratio. 48 hours after electroporation, selective 
media containing Blasticidin was added. After a fortnight, cells were ready to be passaged for the 
first time and simultaneously checked for plasmid expression. 
 
Figure 11: mCherry-expression in L87-HIF-Cherry. Images were taken after 24h incubation at 21% oxygen (A+B) or 2% 
oxygen (C+D). After comparison of the two in bright field (A+C) and fluorescent (B+D) microscopy, it becomes evident that 
there is good activation of the transgene. However, transfection efficiency is mediocre. Images were taken in ten-fold 
magnification with overall identical exposure time. 
As can be observed in figure 11, activation of the transgene is visible under the fluorescent 
microscope. However, transfection efficiency was still not sufficient for the cells to be included in 
further experiments, as in case of a negative result it is uncertain whether this was due to a poor 
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expression rate or due to an actual lack of hypoxia. To resolve this, it was decided to subject the 
transfected cells to FACS analysis and eventually sorting for expression of the transgene. This was 
done in collaboration with the Insititut für Molekulare Immunologie, Helmholtz Zentrum Munich 
(Dr.rer.nat. Dipl-Biol. J.J. Mysliwietz, Prof. Dr. rer.nat. E.Nössner). At the time, the transfected cells 
were analyzed by FACS, only 1.1% expressed the transgene under normoxia, and 2.7% under 
hypoxia (see figure 12). Subsequently, cells were expanded in 300cm2 flasks to a total number of 15 
million and subjected to FACS sorting two weeks after the initial analysis. For the sort, cells were not 
incubated in hypoxia beforehand as the aim was to select cells with the highest transfection 
efficiency and expression rate. With an expression rate of 0.9%, 13.000 cells remained that 
expressed the transgene (see figure 13). These cells were plated out on 96-well plates, applying 
limited dilution aiming for single clones. After a few more days, cultured in selective medium, the 
cells began to grow out in wells and were tested for transgene activation by incubating them at 2% 
oxygen for 24 hours. Fluorescence microscopy of the clones resulted in two of them, B12 and C10, 
being transfected to a satisfactory result (see figure 14).  
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Figure 12: Transgene expression in L87-HIF-Cherry, analyzed by FACS. (A) Empty L87 cells were used as a negative control 
in order to set the gate for mCherry expression. (B) L87-HIF-Cherry incubated under normoxic conditions were analyzed by 
FACS using the same settings established by analysis of empty L87. 1.1% of the cells identified as viable before came up in 
the gate set for mCherry expression. (C) L87-HIF-Cherry incubated under hypoxic conditions (2% oxygen) were analyzed by 
FACS using the same settings established by analysis of empty L87. 2.7% of the cells identified as viable before came up in 
the gate set for mCherry expression.  
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Figure 13: Selection of cells with sufficient transgene expression by FACS. (A) FACS analysis of empty L87 cells in order to 
set the gate for mCherry expression. (B) L87-HIF-Cherry that were incubated under normoxic conditions were analysed and 
sorted by FACS for transgene expression. Cells coming up in the SSC-A/mCherry-window made up 0.6% of all cells earlier 
identified as viable. These cells were collected in a 1.5ml-tube containing culture media with 20% FCS and immediately 
stored on ice for transport.  
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Figure 14: Clones B12 and C10 in light and fluorescence microscopy: All images were taken in ten-fold magnification with 
identical exposure times. (A)+(B) Clone B12 incubated in 21% oxygen for 24 hours. (C)+(D) Clone C10 incubated in 21% 
oxygen for 24 hours. (E)+(F) Clone B12 incubated in 2% oxygen for 24 hours. (G)+(H) Clone C10 incubated in 2% oxygen for 
24 hours. 
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3.2.4 Creation of spheroids from Hepatocellular Carcinoma Cells and MSCs 
To study the behavior of MSC in experimental settings that more closely resemble tumors, a system 
was established that was able to render a reproducible in vitro tumor model. To this end, a series of 
preliminary experiments (data not shown) was performed to generate spheroids from the 
hepatocellular carcinoma (HCC) cell line Huh7. To grow spheroids, the Huh7 cells were distributed in 
culture dishes that had been coated with polyHEMA (see chapter 2.2.1.4). Thus, they were unable to 
attach to the plastic, but instead grew into spheroids from single cells. After 6 to 10 days in culture, 
spheroids made from Huh7 cells typically reached a size of 400 to 600 µm. 
3.2.4.1 Huh7- and L87-spheroids merge in co-culture 
The first experiments investigated the potential interaction between Huh7 and MSC, by co-culture 
experiments with spheroids. To this effect, spheroids were grown from both Huh7 and MSC (L87) 
that had been stained with CMTMR and CMFDA, respectively, to distinguish them using fluorescent 
microscopy. After 24 hours of co-culture, the spheroids had grown into a single larger spheroid that 
contained both CMTMR- and CMFDA-stained cells (see figure 15). 
 
Figure 15: Spheroids from Huh7 and L87 in co-culture. Huh7 and L87 cells were harvested, stained with fluorescent 
markers CMTMR (Huh7, orange) and CMFDA (L87, green) and plated out in limited dilution in 96-well plates coated with 
polyHEMA on day 1. On day 2, most wells contained a single spheroid, which could easily be extricated. A new 96-well 
plate was populated with one Huh7- and one L87-spheroid each. Images (A)-(C) all show the same well and were taken 
shortly afterwards. On day 3, after 24 hours in co-culture, images (D)-(E) were taken, which all show the same well again. 
 
57 
 
 
3.2.4.2 CMFDA-labeled MSC invade Huh7-spheroids in vitro 
As a next step, MSC invasion of tumor spheroids was studied. The Huh7 spheroids were co-cultured 
with primary human bone-marrow-derived MSC. The primary MSC were stained with the 
fluorescent marker CMFDA. Huh7 spheroids were grown as described above using polyHEMA-
coated culture dishes. CMFDA-stained MSC were added to the media and the spheroids incubated 
for 72 hours before being embedded and sectioned using a cryotome. Figure 16 shows images taken 
with the sections viewed under a fluorescent microscope. The results show an efficient invasion of 
the primary MSC directly into the core of the spheroid. 
In the next set of experiments, Huh7 spheroids were incubated with pimonidazole and cryosections 
were stained with a pimonidazole complex antibody and a fluorescent secondary antibody. 
Pimonidazole is a 2-nitroimidazole that is reductively activated in hypoxic cells and subsequently 
forms stable complexes with thiol-groups in other molecules that can be detected by 
immunohistochemistry (see chapter 2.2.1.4). It is used as a marker for cellular hypoxia. The 
complexes do not dissociate when the cells become reoxygenated, as may be the case with HIF1α. 
Figure 17 shows strong pimonidazole staining of the center of a Huh7 spheroid along with invasion 
by CMFDA-labelled primary MSC.  
These experiments show that tumor spheroids serve as a good system to investigate invasion by 
MSC and can be relied on in further studies involving MSC stably expressing a reporter transgene. 
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Figure 16: Immortalized MSC invading Huh7 spheroids in co-culture. Spheroids from Huh7 have been grown for eight 
days in polyHEMA-coated culture dishes. For an additional three days, spheroids were co-cultured with CMFDA-stained 
immortalized MSC (green). For analysis, spheroids were fixed with formalin and embedded in OCT compund for cryo-
sectioning. 18µm-cryoslides were stained with DAPI (cell nucleuses, blue) for fluorescence microscopy.    
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Figure 17: Immortalized MSC invading pimonidazole-labelled Huh7 spheroids in co-culture. Spheroids from Huh7 have 
been grown for eight days before adding pimonidazole-HCl to the media. For an additional five days, spheroids were co-
cultured with CMFDA-stained immortalized MSC (green). For analysis, spheroids were fixed with formalin end embedded 
in OCT compound for cryo-sectioning. 18µm-cryoslides were stained with pimonidazole-antibody overnight and Alexa 
Fluor® 594 (red) as secondary antibody as well as DAPI (cell nucleuses, blue) for fluorescence microscopy. 
 
3.2.5 Invasion assay with Huh7-spheroids and CMFDA-labelled L87-HIF-Cherry 
When a system for producing and analyzing experimental tumor spheroids, as well as a MSC line 
engineered with a reporter gene under the influence of a hypoxia-responsive promoter had been 
established, the two tools were combined to determine if the HIF-responsive MSC induced the 
reporter gene in response to spheroid invasion. For this experiment, the L87-HIF-Cherry clone B12, 
as described in chapter 3.2.3.2, was used as the basis for MSC-based control spheroids. As observed 
in figure 18, the L87-HIF-Cherry formed spheroids that showed activation of the transgene in the 
MSC cells that were in the center, hypoxic regions of the spheroid.  
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The next stage of experiments used spheroids grown from the Huh7 cell line incubated with the 
established L87-HIF-Cherry cell line. For this experiment, the L87-HIF-Cherry clone C10, (3.2.3.2) was 
used. Huh7 spheroids were grown and then transferred to 1.5ml tubes filled with culture media. 
Next, the L87-HIF-Cherry, previously stained with CMFDA, were added to the tubes and the latter 
were placed on a roller plate for two hours for distribution and attachment of MSC to the surface of 
the spheroids. Afterwards, the spheroids were transferred back into 96-well plates, with one 
spheroid per well, and incubated for 72 hours. For analysis, spheroids were embedded and 
sectioned using a cryotome. Figure 19 shows images taken with the sections viewed under a 
fluorescent microscope. It can be observed, that L87-HIF-Cherry efficiently invade the tumor 
spheroids, and also activate the hypoxia-responsive promoter and thus the transgene mCherry once 
they encounter hypoxia within the spheroid. The L87-HIF-Cherry cells that do not activate the 
transgene, appear green under the fluorescent microscope, while the ones activating the transgene 
appear orange/red.  
 
Figure 18: Spheroids from L87-HIF-Cherry. Spheroids were grown for x days before being fixed in formalin and embedded 
in OCT compound for cryo-sectioning. 18µm-cryoslides were stained with DAPI (cell nucleuses, blue). Red fluorescence 
indicates activation of the transgene mCherry within the spheroid and thus cellular hypoxia.  
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Figure 19: L87-HIF-Cherry invading Huh7 spheroids in co-culture. Huh7-spheroids were grown for 8 days in a polyHEMA-
coated culture dish. For the invasion assay, Huh7-spheroids were singled out and transferred to a 1.5ml-tube filled with 
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culture media. L87-HIF-Cherry were harvested, labelled with 10µM CMFDA and added to the tube at a fixed cell number of 
25.000 cells per tube, to a total amount of 50µl of culture media. The tubes were then placed on a roller plate for two 
hours. Afterwards, the culture media, along with L87-HIF-Cherry unable to attach to the spheroid, was carefully removed 
from the tubes and replaced by fresh media. This washing procedure was repeated three times. The spheroids were then 
gathered in a pipette tip with 100µl culture media and transferred into a single well of a 96-well-plate for incubation at 
37°C for 48 hours. After that time, all spheroids were transferred in a single 1.5ml-tube, in order to be embedded together 
in OCT compound for further processing. Cryotome cassettes were stored at -20°C. 16µm slices were cut with a cryotome 
and after formalin fixation the slides were stained with DAPI (blue) for cell nucleuses. For analysis, the slides were 
mounted in 50%-glycerin-0.2%NPG-PBS and observed under the fluorescent microscope. (A)-(E) all show L87-HIF-Cherry 
have invaded the spheroid and are expressing the transgene mCherry. (C) Shows a single cell of the CMFDA-stained L87-
HIF-Cherry cell line that appears not to be expressing the transgene and is therefore of a rather green than red 
fluorescence. It is located further away from the center of the spheroid than the red L87-HIF-Cherry. Spheroid size has 
been measured using a scaling tool and amounts to 574µm. 
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3.3 Heat Shock Protein 70b (HSP70b) can be activated by hyperthermic treatment 
Hyperthermia is under development as an adjuvant treatment strategy for some solid cancers by 
creating localized hyperthermia in the region of the tumor (see chapter 1.2.3). We sought to 
determine if externally applied hyperthermia could be used to activate transgenes in engineered 
MSC. If so, the general principle could be used for the controlled regional expression of MSC-based 
therapy transgenes in the context of hyperthermic treatment. 
3.3.1 Design of two different heat shock responsive promoters: endogenous HSP70b and 
HSP70b-responsive 
To this end, a gene promoter was needed that would work in a similar manner to that seen for the 
hypoxia-responsive promoter detailed above. The hypoxia-responsive promoter contains six binding 
sites for the HIF1α transcription factor. A similar synthetic promoter was obtained that contained 
heat-shock-responsive elements upstream of a minimal promoter (pHSE-SEAP by Clontech®). It was 
provided by Prof. Manfred Ogris (Department of Pharmacy, LMU Munich). He also provided a 
second potential vector that used the endogenous HSP70b-promoter (pHSP70b-βgal by StressGen®). 
Both promoters were cloned into a pGL3-Basic expression vector (Promega®), which uses firefly 
luciferase as a reporter gene. Figure 20 shows the design of both these plasmids.  
A 
 
B 
 
Figure 20: Plasmid maps of pGL3-HSE and pGL3-HSP70b. These plasmids represent two different approaches to heat 
response. (A) PGL3-HSE carries a heat shock responsive promoter that is made of three consecutive heat shock response 
elements (HSE) and a TATA-like promoter (PTAL) region from the Herpes simplex virus thymidine kinase (HSV-TK) promoter. 
(B) PGL3-HSP70b carries the endogenous HSP70b-promoter that is directly activated by heat.  
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3.3.2 In vitro stimulation in a 42°C waterbath: The endogenous HSP70b-promoter responds 
more efficiently 
The two potential heat-responsive promoters were compared by transiently transfecting MSC (L87 
cells) using lipofectamine and pGL3-HSE or pGL3-HSP70b vectors. pRL-CMV was co-transfected at a 
1:50-ratio to control for transfection efficiency. The following day, the transfected cells were 
subjected to heat shock for 30 minutes, using a 42°C water bath. Afterwards, the plates were 
returned to the 37°C-incubator and incubated for a further 24 hours, before lysis and analysis of 
luciferase expression. Figure 21 shows the results. Both promoters showed a statistically significant 
increase in luciferase activity following heat shock, however, the endogenous HSP70b-promoter 
yielded a much more promising result showing a ten-fold induction of the reporter gene, as 
compared to a three-fold induction obtained with the HSE-promoter. Therefore, the HSP70b-based 
vector was used for subsequent experiments. 
A 
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Figure 21: In vitro stimulation of heat shock response. Cells (L87) were seeded out in 96-well plates on day 1. On day 2, 
with 80% confluence, transient transfection was performed by using lipofectamy according to protocol. 6 hours after 
transfection, culture media was exchanged and cells were incubated for 24 hours at 37°C. On day 3, cells were subjected 
to heat shock for 30 minutes by using a 42°C water bath. Cells were subsequently returned to the 37°C incubator and 
incubated for another 24 hours, before being analyzed for luciferase activity. The experiment was repeated several times. 
Statistical analysis was performed by applying the Mann-Whitney-U-Test. (A) The heat shock responsive promoter HSE 
only carried a threefold increase in luciferase activity after the 30 minute exposure to 42°C. P=0.0079. (B) By contrast, the 
endogenous HSP70b promoter carried a ten-fold increase in luciferase activity after 30 minute exposure to 42°C. P=0.0079 
3.3.3 Integrating Sleeping Beauty into the backbone: pcDNA-ITR-HSP70b-Cherry/Gaussia/TK 
As a last step in the characterization of these new potential tools for the generation of MSC-based 
therapy procedures, the HSP70b promoter was adopted for use with the Sleeping Beauty-modified 
Multisite Gateway® Pro Plus system. The HSP70b endogenous promoter was amplified by PCR with 
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compatible ends for subcloning into the vector system. The primers were designed to generate the 
necessary attB sites on both ends, for the BP reaction. The resulting entry clone is shown in figure 
22-A on the following page. The entry clone pENTR221-HSP70b was then paired with the entry clone 
pENTR221-Cherry (see figure 9-B on page 49) in an LR reaction with the destination vector 
pcDNA6.2PLITRBlasti-Dest, which contained the sleeping beauty transposition sites in the backbone. 
The resulting expression vector pcDNA-ITR-HSP70b-Cherry thus carried the endogenous HSP70b 
promoter in front of the mCherry red fluorescent protein as well as the sleeping beauty 
transposition sites and a blasticidin resistance gene in the backbone (see figure 22-B) Correct 
integration of the PCR amplicon in the entry clone as well as the two entry clones in the expression 
vector was verified by performing restriction digests and sequencing performed by GATC (data not 
shown).  
The next step will be to stably transfect MSC with this plasmid and perform control studies. 
However, these future experiments could not be included in this study due to a lack of time. The 
system is now under study in the Nelson/Spitzweg labs of the Medizinische Klinik und Poliklinik IV in 
the context of a Sander Stiftung grant. 
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Figure 22: Plasmid maps of pENTR221-HSP70b and pcDNA-ITR-HSP70b-Cherry. (A) pENTR221-HSP70b is an entry clone 
that contains the attL1 and attR5 sites (red) flanking the HSP70b-promoter (purple). (B) pcDNA-ITR-HSP70b-Cherry is the 
expression vector resulting from recombination of pcDNA6.2PLITRBlasti-Dest with the entry clones pENTR221-HSP70b and 
pENTR221-Cherry during the LR reaction. Sleeping beauty transposition sites are marked in pink, att recombination sites 
are marked in yellow.  
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4 Discussion 
4.1 Genetically engineered MSC are suitable agents in targeted therapy 
Malignant diseases range among the top three causes of death worldwide. In Germany, 51% of men 
and 43% of women will suffer from malignant disease during the course of their life, and one in four 
men or one in five women will die from cancer (Robert-Koch-Institut 2013). With very few patients 
eligible for curative surgery, cancer therapy still widely relies on chemo- and radiation therapy. Both 
are systemic therapies with significant detrimental effects on healthy tissue. Therefore, the need for 
individualized, tumor-targeted therapies has become more and more pressing.  
The concept of using MSC as targeted vehicles in tumor therapy is based on their potential to 
migrate towards injured and malignant tissue. However, the scientific community remains at odds 
over the potential effects of the application of MSC on tumor progression (Klopp 2011). But it is now 
established that engineering MSC to carry therapeutic agents or express therapeutic genes can 
render them effective weapons in cancer therapy (Hagenhoff 2016). Studeny et al used adenoviral 
transduction to infect MSC with adenoviruses carrying a construct that maintains β-interferon under 
the control of a constitutively active promoter, the cytomegalovirus (CMV). Successfully infected 
MSC then expressed high levels of β-interferon, a strongly anti-proliferative cytokine. They were 
injected intravenously via the tail vein in mice bearing metastatic melanomas. This served to 
significantly prolong survival. Interestingly, this could be achieved without toxic serum-levels of β-
interferon, which constitutes an insurmountable obstacle in systemic interferon therapy of solid 
tumors (Studeny 2002, Studeny 2004). In a similar approach relying on a different cytokine, 
interleukin-2, Nakamura et al used MSC infected with adenoviruses expressing the immune-
regulator in glioma-bearing rats. Again, survival could successfully be prolonged (Nakamura 2004). 
Other research groups focused on using genetically engineered MSC to activate prodrugs within the 
tumor. Miletic et al, for instance, used a rat glioma model and injected HSV-TK-expressing MSC 
subcutaneously into the vicinity or into the tumor itself and detected a therapeutic effect by 
positron emission tomography (Miletic 2007). Herpes simplex virus thymidine kinase (HSV-TK) can 
activate previously administered ganciclovir and is deemed a suicide gene that kills surrounding cells 
in a bystander effect, as outlined in chapter 1.1. Another prodrug that has been used in this way is 5-
Fluorocytosine, with cytosine-deaminase as the equivalent to HSV-TK. Kucerova et al chose this 
approach in their study of the therapeutic efficacy of adipose tissue-derived MSC that were 
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retrovirus-transduced with yeast cytosine deaminase and administered intravenously in colon 
cancer-bearing mice. 5-Fluorocytosine is far less toxic than its famous relative 5-Fluoruracil, a potent 
yet highly toxic cytostatic drug. Upon application of 5-Fluorocytosine, it was converted to 5-
Fluoruracil by MSC-expressed cytosine deaminase. As a result, significant growth inhibition in the 
absence of relevant side effects was recorded (Kucerova 2007). TRAIL (TNF-α related apoptosis 
inducing ligand) is a cytokine that is able to specifically induce apoptosis in the majority of tumor 
cells, while most normal tissues do not possess adequate receptors (LeBlanc 2003). Shah et al have 
engineered a recombinant form of TRAIL, named S-TRAIL, that can be secreted instead of being 
incorporated in the plasma membrane, thus increasing tissue concentrations (Shah 2004). S-TRAIL-
expressing MSC were either implanted in mice simultaneously with glioma cells or added later on in 
the vicinity of existing tumors. Mice that received TRAIL-MSC survived significantly longer than the 
control animals (Sasportas 2009) 
All of these studies exploited the homing capacities of MSC in an effort to create new therapeutic 
approaches aimed at increased specificity and efficacy combined with reduced toxicity. Our group 
has looked at ways to further refine these strategies by using the tumor microenvironment to 
induce the expression of therapeutic transgenes in engineered MSC. The aforementioned concepts 
all have one thing in common: They rely on constitutively expressed therapeutic genes. Our goal was 
to equip these therapeutic genes with a promoter that becomes activated once the MSC have 
reached the tumor. This serves to protect the MSC from their dangerous cargo until they have 
reached the tumor; and helps reduce undesirable side effects of MSCs that traffic to non-tumor 
tissues.  
One approach for stalling tumor growth is to target the tumor microenvironment, also referred to as 
tumor stroma. The proliferation of tumor cells relies on neovascularization. MSC, which have 
infiltrated the stroma help contribute to the establishment of new vessel growth, a process that is 
regulated by angiopoietin-1, a vascular growth factor, and Tie-2, its receptor. Our group was able to 
show that MSC, engineered to express a red fluorescent protein under the control of a Tie-2 
promoter, start to express Tie-2 once they have reached the tumor stroma, receive an angiopoietin 
signal and differentiate into endothelial cells. Once the red fluorescent protein had been exchanged 
with HSV-TK, ganciclovir administration after MSC injection served to significantly reduce tumor 
growth and prolong survival in pancreatic and breast cancer mouse models (Conrad 2011).  
69 
 
 
Neovascularization is by no means tumor-specific, but instead tissue-specific. However, the 
combination of homing of MSC and targeting transgene expression at their destination is what 
makes this therapeutic approach so precise.   
4.2 Tissue-specific targeting increases efficacy and reduces toxicity 
4.2.1 Targeting the inflammatory tumor milieu: Rantes/CCL5 
A refined targeting strategy used for MSC gene delivery by our group utilizes the inflammatory 
milieu within a tumor for upregulation of the therapeutic transgene. CCL5 (Rantes) is a chemokine 
that has been shown to play a role in tumor progression and metastasis. It is secreted both by tumor 
cells and by cells infiltrating the tumor stroma such as MSC (Karnoub 2007, Aldinucci 2014). Reports, 
reviewed by Aldinucci et al and Borsig et al, have described the role of CCL5 in tumor progression as 
that of a coordinator of the immune response, which induces the stroma to switch from a tumor-
suppressive to a tumor-supportive environment. It does so mainly by attracting immune-modulating 
cells to the stroma, enhancing the motility of cancer cells and remodeling the ECM. All this leads to 
increased local invasiveness and promotes metastasis to distant organs (Aldinucci 2014, Borsig 
2014). Zischek et al used a version of the endogenous human CCL5 promoter to drive either reporter 
or therapeutic transgene (HSV-TK) expression in stably transfected immortalized MSC. The in vivo 
model used for these studies made use of syngeneic mice bearing an orthotopic pancreatic 
carcinoma, which is characterized by a distinctive amount of dense stroma. Tumors of mice injected 
with MSC carrying the CCL5-reporter construct showed high expression of the reporter gene in 
tissue sections of the excised tumors. To test for efficacy of the CCL5-HSV-TK construct, tumor 
bearing mice were subjected to three cycles of MSC administration and – following a 72-hour lag 
intended for successful recruitment and transgene activation – received systemic ganciclovir 
injections on three consecutive days. This led to significant reduction of tumor growth and 
metastasis to peritoneum, spleen and liver. Importantly, reporter gene expression by MSC was 
detected in spleen, lymph nodes, thymus, skin and gut when under control of the constitutive CMV-
promoter, but not when under the control of CCL5. This shows that while engineered MSC do 
infiltrate other non-malignant tissues , activation of the CCL5 promoter-driven transgene is largely 
restricted to malignant tissues (Zischek 2009, Hagenhoff 2016) 
In a similar approach, Knoop et al used the same CCL5 promoter but driving the sodium iodide 
symporter (NIS) transgene. The NIS protein is normally expressed by follicular cells of the thyroid 
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gland and is responsible for iodide uptake by thyroid cancer cells. This biology has revolutionized 
radionuclide-based therapy for this tumor and made differentiated thyroid cancer one of the most 
curable of solid tumors. Typically, radioactive iodine 131I is administered orally after total 
thyroidectomy and local lymphadenectomy. Therefore, radioiodine therapy serves the purpose of 
eradicating residual thyroid tissue and potential distant metastases (Spitzweg 2002). As was detailed 
earlier, NIS is expressed predominantly by follicular cells in the thyroid gland, but also to a much 
lesser extent in salivary glands, gastric mucosa, lactating mammary gland, choroid plexus and ciliary 
body of the eye (Hingorani 2010).  
Knoop et al showed that MSC stably transfected with a construct carrying the NIS gene under the 
control of the CCL5 promoter can make solid malignancies accessible to radioiodine therapy. Mice 
bearing HCC tumor xenografts (Huh7 cell line) received three doses of CCL5-NIS-MSC at intervals of 
four days, and 131I was administered 72 hours after the last injection of MSC. This served to 
significantly stall tumor growth macroscopically, which was confirmed in immunohistochemical 
analysis of tissue sections, where tumors treated with CCL5-NIS-MSC and 131I showed less 
proliferation in the Ki67-index and lower vessel density (Knoop 2011, Knoop 2013). In a recently 
published paper, Knoop et al investigated the applicability of the CCL5-NIS-MSC system to target 
metastatic disease. To this end, a metastatic cancer mouse model was created by injecting the 
human colon cancer cell line LS174t cells into the spleen of mice and then performing a splenectomy 
two days later. Over these two days LS174t cell effectively “seed” the liver thus modeling tumor 
metastases. Treatment of tumor-bearing mice with CCL5-NIS-MSC and 131I showed efficacy not only 
in preventing formation of new metastases, but also in reducing already existing metastases (Knoop 
2015). An interesting aspect of these findings is that it potentially also opens up new ways of 
diagnosing metastatic disease, as apparently MSC not only home to major solid malignancies but 
also towards small areas of malignant growth, which may not be detectable by conventional imaging 
technologies currently in use in the diagnosis and treatment of thyroid cancer.  
These studies show that the concept of MSC equipped with CCL5-driven therapeutic genes works 
well in animal models in the context of both pancreatic and hepatocellular carcinoma. The purpose 
of the present study was to better characterize the molecular mechanisms involved in activation of 
the CCL5 promoter within the tumor microenvironment. As was discussed earlier, CCL5 activation 
within a tumor is thought to derive from the intense cytokine crosstalk that occurs between cancer 
cells and non-malignant cells that defines an inflammatory/hypoxic milieu, with production of TNF-
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α, TGF-β, γ-IFN and IL-1β. Together with the fact that MSC do not home to tumors because they are 
malignant, but rather because they resemble chronic inflammatory sites, this raises the question of 
possible side effects of CCL5-directed MSC therapy. As was pointed out earlier, Zischek et al 
demonstrated incorporation of transplanted MSC into non-malignant tissues, namely secondary 
lymphatic tissues, skin and mucosa (Zischek 2009). While activation of the CCL5-driven transgene 
expression was found to be largely limited to the tumor environment, it remains to be seen how, for 
instance, skin and mucosa that have been impaired or damaged by therapy prior to MSC treatment 
could influence transgene expression. This may be especially important with regards to 
gastrointestinal mucosa, which as a highly replicative tissue suffers greatly from radiation and 
chemotherapy. The pathophysiology of gastrointestinal mucositis represents one of the main non-
hematologic side effects of anti-cancer therapy (Sonis et al). Increased serum levels of TNF-α and IL-
1β correlate with the extent of mucositis in patients undergoing chemotherapy. Therefore, 
gastrointestinal mucosa that is affected by a multitude of aggressive treatment regimens the 
patients received before might pose a risk in terms of possible side effects as the RANTES promoter-
driven transgene may be activated in this inflammatory milieu.   
4.2.2 Targeting the hypoxic tumor microenvironment: HIF-1α 
CCL5 up-regulation is a cellular stress response. A rapidly growing tumor that develops ahead of its 
vasculature contains areas of severe hypoxia. One of the aims of this study was to find out whether 
CCL5 activation in MSC that have infiltrated the tumor stroma, as was demonstrated by Zischek et 
al, is caused by tumor hypoxia. Our results show that this is not the case. However, the idea of 
targeting tumor hypoxia is appealing, seeing as it correlates with increased invasiveness and poor 
prognosis. The transcription factor HIF-1α is a central player in cellular response to hypoxia. It is 
enhanced in a range of different tumors, depending on oxygen levels within the tumor stroma, but 
can also be activated independently of oxygen levels (as detailed in chapter 1.2.2).  
To evaluate whether a transgene controlled by a HIF-responsive promoter (consisting of six HIF-
responsive elements (HRE) and a minimal TK promoter) would show efficacy in engineered MSC-
based tumor therapy, it was necessary to demonstrate that MSC enhance HIF-1α expression in the 
same way as their malignant counterparts, once they have infiltrated the tumor stroma. After all, 
bone marrow-derived MSC usually reside within the hypoxic confines of the hollow bones. Our 
results showed an approximately ten-fold induction of HIF-1 in MSC exposed to severe hypoxia (2% 
O2) or the hypoxia-mimicking chelator cobalt chloride in vitro. The HCC-Huh7 spheroid model 
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provided an opportunity to study functional expression of HIF-1 in more physiologic circumstances. 
The engineered MSC where shown to invade the spheroids and to induce expression of HIF-1α-
driven reporter transgene in the hypoxic center of the experimental tumor.   
In vivo validation studies were subsequently performed in collaboration with Müller et al using the 
same promoter (Mueller 2016). The results demonstrate that MSC engineered with HIF-NIS injected 
into mice bearing HCC xenografts successfully express the transgene once they have infiltrated the 
tumor stroma (Mueller 2016). The study was performed on subcutaneous as well as orthotopic 
Huh7 xenografts. Both models showed strong radioiodine uptake, though a 2-fold increase was 
measured in orthotopic xenografts compared to subcutaneous. This was reproduced in a second set 
of experiments applying a therapeutic regime consisting of repeated MSC-HIF-NIS administrations 
and 131I-injections. While mice bearing the subcutaneous xenografts showed no significant reduced 
tumor growth or prolonged survival as compared to the control group, radioiodine uptake in 
orthotopic xenografts was sufficient to stall tumor growth and improve survival (Mueller 2016). The 
study demonstrates that the concept of using tumor hypoxia for MSC-based targeted therapy is a 
valid approach. It is assumed that an endogenous hypoxia-sensitive promoter may offer better 
induction and more robust expression levels. Downstream gene targets of HIF-1 such as VEGF, for 
instance, may hold more promise and are currently under investigation in the Nelson lab.  
This approach was inspired by the observation that rapidly growing primary tumors develop areas of 
severe hypoxia. In a wide range of tumors, up-regulation of HIF-1α correlates with poor prognosis. 
An interesting aspect of radiation biology was highlighted by Harada et al in a study on tumor 
hypoxia in colon carcinoma: It showed that tumor cells furthest away from oxygen-providing blood 
vessels, that were in hypoxic regions but were not expressing HIF-1 before radiation, acquired HIF-1 
activity after radiation, which enabled them to migrate towards blood vessels in order to access 
oxygen. This is interpreted as one of the mechanisms underlying tumor recurrence after initially 
successful radiation therapy (Harada 2012). Deeply hypoxic tumor cells are able to survive radiation 
due to HIF-1-unrelated effects, but HIF-1 up-regulation after radiation may enhance tumor 
aggressiveness. MSC engineered to express a suicide gene under the control of a hypoxia-responsive 
promoter, applied together with radiation therapy, could help overcome this obstacle.  
In mouse models, the CCL5-TK- and CCL5-NIS-MSC have been shown to have a therapeutic effect in 
primary tumors of pancreatic and hepatocellular origin as well as metastatic disease. The size of 
metastatic filiae can range from microscopically small colonies to vast solid tumors that are as big as 
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or even bigger than the primary tumor. However, oxygen shortage is more a question of growth 
speed than of the actual size of the tumor. Therefore, the grade of hypoxia in metastases 
presumably varies. On the other hand, several reports have described loss of tumor suppressor gene 
expression as well as gain of oncogenes can be sufficient to up-regulate HIF-expression (chapter 
1.2.2).  Whether a hypoxia-driven construct in MSC is as functional in metastatic disease as its CCL5-
driven counterpart remains to be demonstrated.  
Analogous to the potential side effects of a CCL5-driven therapeutic transgene in MSC, the extra-
tumoral activation of a hypoxia-sensitive construct is mainly a question of precursory tissue damage 
through previous treatment regimens. Lymphatic tissue like spleen and lymph nodes, but also lung 
have been shown to be potential targets of circulating MSC, even though it is assumed that the 
micro-vasculature in these organs is responsible for extravasation of MSC rather than a directed 
chemotactic response. However, the extensive micro-vasculature in these tissues also maintains a 
steady flow of oxygen, therefore, hypoxic activation of the transgene is unlikely to occur. Chronic 
inflammation, for example of the gastrointestinal mucosa, is a common complication of 
chemotherapy, and could potentially cause unwelcome side effects in therapy with CCL5-MSC. By 
contrast, these effects are unlikely to induce a HIF-responsive promoter in MSC. Inflammation is 
associated with increased perfusion, and HIF-1 is not known as being involved in the inflammatory 
response. As described in chapter 1.1, patients suffering from myocardial infarction or cerebral 
ischemia have benefited to some extent from treatment with MSC. Therefore, patients presenting 
with a history of coronary artery disease, peripheral ischemic disease or transient cerebral ischemic 
attacks, might not be suitable candidates for this therapeutic approach.    
4.2.3 Enhancing control of transgene activation through external activation: HSP70b 
A vector system that would allow the induced expression of a therapeutic gene by MSC in response 
to external stimulation is an interesting idea. Hyperthermia is currently under investigation as an 
adjunct therapy to existing therapeutic regimes. Hyperthermia increases local perfusion and thus 
drug availability. Patients undergoing radiation therapy benefit from the increased oxygenation that 
enhances the local effect (chapter 1.2.2), while intratumoral drug delivery is more efficient in 
patients receiving chemotherapy (Wust 2002). Several studies have also highlighted the 
immunomodulating effects of hyperthermia. As described in chapter 1.2.3, extracellular HSP70 
functions as a molecular chaperone in presenting tumor antigens to dendritic cells and leukocyte 
recruitment to the tumor microenvironment is enhanced by fever-range hyperthermia (Fisher 2011, 
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Jolesch 2011). Using heat-responsive promoters to drive therapeutic transgenes in response to 
regional hyperthermia would allow a tumor-specific induction of the transgene. Any potential 
beneficial effect of hypothermia on malignant growth, as previously demonstrated, could be added 
to the effect achieved through the therapeutic transgene (Haen 2011). Our results show that the 
endogenous HSP70b promoter is much stronger induced in MSC exposed to hypothermia, as 
compared to the synthetic heat-shock responsive promoter.  
4.3 Clinical applicability: Individualized therapy  
4.3.1 MSC 
MSC can be harvested and isolated using a straightforward procedure involving a bone marrow 
aspirate, preferably from the iliac crest. After spinning down and washing the aspirate, MSC are 
isolated as they are the only cells that strongly attach to the plastic surface of a culture vessel (Beyer 
Nardi 2006). Subsequently, the identity of MSC can be confirmed by their pattern of cell surface 
markers, as described in chapter 1.1. After a lag phase of about 3-5 days in culture, cells begin to 
spread out and, with the first passage, can be transfected with the desired construct. The MSC can 
be harvested from the patient as part of an autologous transfer. If, however, the clinical condition of 
the patient does not allow bone marrow aspiration, the MSC can potentially be harvested from a 
donor. As explained in chapter 1.1, MSC do not provoke an immunogenic reaction, due to their lack 
of major histocompatibility complex MHC II.  
Recently, Niess et al published the first study protocol that describes a phase I/II clinical trial with 
the aforementioned CCL5-TK construct incorporated into autologous MSC. The treatment regimen 
allows for three intravenous administrations of the engineered MSC in the space of 21 days, each 
followed by ganciclovir applications on three consecutive days, starting 48 hours later. This is hoped 
to provide sufficient time for the MSC to invade the tumor stroma and for the ganciclovir to reach its 
target cells (Niess 2015). The purpose of this clinical trial is to examine possible side effects of the 
therapeutic approach and to determine its safety. One of the questions that remain to be answered 
concerns the fate of MSC that are not being destroyed in the course of ganciclovir treatment, 
possibly because they do not activate the transgene. It is unclear whether they can persist within 
the patient, travel along with the blood stream or possibly settle down elsewhere, for example in 
the bone marrow.  
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4.3.2 Tumors 
One particular strength of this potential therapeutic approach is its versatility. The goal of 
individualized cancer therapy is to increase specificity of treatment while simultaneously reducing 
side effects. The technique of engineering MSC with tumor-specific therapeutic genes opens up new 
possibilities to customize tumor therapy. As the comparison of three targeting strategies in this 
study showed, each promoter that has been used showed its potential in different circumstances.  
The Rantes/CCL5-promoter has been studied by our group in pancreatic carcinoma, breast cancer, 
metastatic carcinoma and hepatocellular carcinoma models. In each model, it was demonstrated 
that a therapeutic gene, whether it was herpes simplex thymidine kinase or NIS, was expressed by 
MSC within the tumor when driven by the CCL5-promoter. Those could include difficult-to-treat 
tumors such as malignant melanoma, a skin cancer that metastasizes early and thus renders many 
patients in a palliative treatment situation at the time of diagnosis. The primary tumor is often very 
small (Thompson 2005). Hypothetically, the CCL5-MSC could not only be used as a therapeutic tool 
in this scenario, but also potentially as a diagnostic means to detect micro-metastases that are 
under the radar of positron emission tomography, because they are too small to register a 
significant increase in metabolism (e.g. by using the NIS theranostic gene).  
On the other hand, tumors that show extensive growth at the primary side but tend to metastasize 
late may be potential indicators for the use of MSC engineered with a hypoxia-driven transgene. In 
this setting, the MSC could be used to stall tumor growth, or even to downstage the primary tumor 
to allow for a complete resection. As was detailed in chapter 1.3, hepatocellular carcinoma is a 
tumor not prone to chemo- or radiation therapy, with resection or liver transplantation being the 
only curative options. Many patients suffering from this disease are listed for liver transplantation, 
but organs are scarce and thus patients often die from the effects of the progressing tumor before 
receiving a suitable organ. Engineered MSC could potentially provide a valid treatment option to 
prolong the time span wherein patients are suitable candidates for organ transplantation.  
Clinical applicability of HSP70b-MSC largely depends on the exact location of the primary tumor. 
Site-specific application of hyperthermia has been the focus of extensive research and several 
clinical trials so far, as reviewed by Wust et al (Wust 2002). For superficial tumors, like lymph node 
metastases, melanoma or breast cancer, local hyperthermia can be created by applying a micro- or 
radiowave-emitting electromagnetic device directly to the skin. Tumors that are accessible via 
implantation of heat-inducing devices are typically located in the head and neck region (esophageal 
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cancer or even glioblastoma) as well as the rectum and pelvis (prostate or cervical cancer). The 
abdomen can be subjected to regional hyperthermia by installing a ring of multiple applicators 
around the patient that are able to increase the temperature quite specifically in deep-seated tumor 
regions. The only feasible approach in patients presenting with metastatic disease is whole-body 
hyperthermia, which can be established by situating the patient in a closed, potentially moisture-
saturated environment, and inducing heat with infrared radiators, for example. However, close 
monitoring and extensive patient care is necessary to keep potential side effects at bay, which occur 
at extreme body temperatures around 42°. The patient needs to be deeply sedated, rehydrated and 
under strong analgesia. Possible side effects include cardiac failure, coagulation disorders and local 
skin burn as well as edema due to fluid over-compensation (Wust 2002). Therefore, the feasibility of 
a therapeutic approach including heat-inducible transgenes delivered to the tumor by MSC strongly 
depends on the site of the tumor and the existence of distant metastasis. Whole-body 
hyperthermia, which would be necessary for transgene activation in metastatic disease, is 
associated with an extensive effort in clinical management and undermines the tumor-specificity of 
the approach. 
To conclude, engineering mesenchymal stem cells with therapeutic transgenes targeting the tumor 
stroma is an exciting approach in the development of individualized cancer therapy. Future research 
by our group will focus on refining the existing targeting techniques and discovering new aspects of 
the tumor microenvironment that can serve as a target.  
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5.2 Abbreviations 
µg micrograms 
µl microliters 
µM micro-molar 
AIF apoptosis-inducing factor 
APAF-1 apoptotic protease activating factor 
APS ammoniumpersulfate 
ATP adenosine triphosphate 
bp base pairs 
Bsd blasticidin 
C celsius 
CaCl2 calcium chloride 
CAF cancer-associated fibroblast 
CD cluster of differentiation 
CIP calf intestine phosphatase 
cm2 square centimeters 
CMFDA 5-chloromethylfluorescein diacetate 
CMTMR chloromethylbenzoylaminotetramethylrhodamine 
CMV cytomegalovirus 
CoCl2 cobalt chloride 
DAPI 4',6-diamidino-2-phenylindole 
DMEM Dulbecco’s Modified Eagle Medium 
DNA deoxyribonucleic acid 
E.coli Escherichia coli 
ECL enhanced chemiluminescence 
ECM extracellular matrix 
EDTA enhanced chemiluminescence 
EGF epithelial growth factor 
EGTA ethylene glycol tetraacetic acid 
ELISA enzyme linked immunosorbent assay 
EMT epithelial-mesenchymal transition 
FACS fluorescence activated cell scanning 
FAP fibroblast-activating protein 
FCS fetal calf serum 
Fe Ferrum 
FGF-2 fibroblast growth factor-2 
FSP fibroblast-specific protein 
GvHD graft-versus-host-disease 
HBV hepatitis B virus 
HCC hepatocellular carcinoma 
HCl hydrochloride 
HCV hepatitis C virus 
HGF hepatic growth factor 
HIF hypoxia-inducible factor 
HLA-DR human leukocyte antigen – antigen D related 
HRE heat-responsive elements 
HSP heat shock protein 
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HSV herpes simplex virus 
IFN interferon 
IgG immunoglobulin G 
IL interleukin 
ITR indirect terminal repeats 
kDa kilo-Dalton 
LB lysogeny broth 
LDHA lactate dehydrogenase A 
MCT-4 monocarboxylate transporter 4 
MHC major histocompatibility complex 
min/’ minutes 
ml milliliter 
mM micromolar 
mmol millimole 
MMP matrix metalloproteinase 
MSC mesenchymal stem cell 
MT1-MMP membrane type 1 metalloprotease 
ng nanogram 
NIS sodium iodide symporter 
nm nanometer 
O2 oxygen 
OCT optimal cutting temperature 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PDGF platelet-derived growth factor 
PDK pyruvate dehydrogenase kinase 
PHD-2 prolyl hydroxylase domain-containing protein 2 
polyHEMA Polyhydroxyethylmethacrylate 
RANTES regulated on activation, normal T cell expressed and secreted 
rpm rounds per minute 
RPMI Roswell Park Memorial Institute 
SDF-1 stroma-derived factor 1 
SDS sodium dodecyl sulfate 
sec/’’ seconds 
SMA smooth muscle actin 
TACE transcatheter arterial chemoembolization 
TAF tumor-associated fibroblast 
TBST tris-buffered saline and tween 20  
TGF transforming growth factor 
TK thymidine kinase 
TNF tumor necrosis factor 
TRAIL TNF-related apoptosis-inducing ligand 
TRIS tris(hydroxymethyl)aminomethane 
U units 
UV ultraviolet 
V volts 
VEGF vascular endothelial growth factor 
vHL von Hippel-Landau 
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WHO world health organization 
x times 
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